CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
10026691,100266915,5,F,20140213,20160427,20140321,20160607,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-20545620,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,,,20160607,,CN,US,ZW,EFAVIRENZ,Hyperbilirubinaemia,100266915,OT,,,100266915,1,20131203,,,,100266915,1,HIV infection
10161197,101611972,2,F,,20160404,20140508,20160407,PER,,US-GILEAD-2014-0101721,GILEAD,,53,YR,A,M,Y,,,20160407,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Dizziness;Nightmare,,,,,,,,,,,101611972,1,HIV infection
10424377,104243772,2,F,20060524,20160628,20140902,20160630,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-21335153,BRISTOL MYERS SQUIBB,,45,YR,,F,Y,,,20160630,,CN,US,JP,EFAVIRENZ,Hypercholesterolaemia;Hyperglycaemia;Nephrolithiasis,104243772,HO,,,104243772,1,20060125,20120523,,,104243772,1,HIV infection
11238812,112388122,2,F,,20160510,20150706,20160511,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-038383,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20160511,,OT,US,US,SUSTIVA,Off label use;Wrong technique in product usage process,,,,,,,,,,,112388122,1,HIV infection
11415550,114155502,2,F,,20160510,20150825,20160513,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2015GSK121403,VIIV,LINGESWARAN A.. ANTIRETROVIRAL TREATMENT INDUCED CATATONIA IN 16-YEAR-OLD BOY.. JOURNAL OF PEDIATRIC NEUROSCIENCES. 2014;9;3:283-285,16,YR,,M,Y,,,20160513,,OT,IN,IN,Efavirenz,Agitation;Brain scan abnormal;Catatonia;Echopraxia;Grimacing;Mutism;Poor quality sleep;Withdrawal syndrome,114155502,HO,,,,,,,,,114155502,1,HIV infection
11594898,115948984,4,F,20150115,20160613,20151005,20160615,EXP,,PE-GILEAD-2015-0174370,GILEAD,,,,,M,Y,,,20160615,,MD,PE,PE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anencephaly;Foetal exposure during pregnancy,115948984,OT,,,115948984,1,20130612,,,,115948984,1,HIV infection
11658562,116585623,3,F,20150420,20160526,20151026,20160530,EXP,,ZA-ROCHE-1648551,ROCHE,,40,YR,,F,Y,55,KG,20160530,,MD,ZA,ZA,EFAVIRENZ,Anaemia;Deep vein thrombosis;Gastroenteritis;Hepatic function abnormal;Hypokalaemia;Leukopenia;Lymphopenia;Neutropenia;Neutropenic sepsis,116585623,HO,,,116585623,1,20150414,20150414,,,116585623,1,Non-Hodgkin's lymphoma
11739957,117399572,2,F,20081101,20160616,20151113,20160624,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-14902696,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,,,20160624,,OT,UG,UG,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,117399572,OT,,,117399572,1,20071008,20080904,,,117399572,1,Antiretroviral therapy
11744743,117447437,7,F,20150115,20160614,20151116,20160617,EXP,,PE-GILEAD-2015-0174369,GILEAD,,31,YR,A,F,Y,82,KG,20160617,,MD,PE,PE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Caesarean section;Maternal exposure during pregnancy,117447437,OT,,,117447437,1,20130612,,,,117447437,1,HIV infection
11867300,118673003,3,F,2012,20160401,20151224,20160406,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2015GSK180022,VIIV,,43,YR,,M,Y,,,20160406,,CN,GB,GB,Efavirenz,Cerebrovascular accident;Cognitive disorder;Depression;Fatigue;Hypokinesia;Intentional self-injury,118673003,OT,,,,,,,,,118673003,1,Product used for unknown indication
11867488,118674883,3,F,2012,20160401,20151224,20160406,EXP,,GB-GLAXOSMITHKLINE-GB2015GSK180022,GLAXOSMITHKLINE,,43,YR,,M,Y,,,20160406,,CN,GB,GB,Efavirenz,Cerebrovascular accident;Cognitive disorder;Depression;Fatigue;Hypokinesia;Intentional self-injury,118674883,OT,,,,,,,,,118674883,1,Product used for unknown indication
11941324,119413243,3,F,20160119,20160323,20160122,20160404,EXP,,MX-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-003946,BRISTOL MYERS SQUIBB,,25,YR,,M,Y,68.4,KG,20160404,,OT,MX,MX,EFAVIRENZ,Ventricular extrasystoles,119413243,OT,,,119413243,1,20151015,20160118,,,119413243,1,HIV infection
12083054,120830542,2,F,20150212,20160429,20160217,20160509,PER,,US-PFIZER INC-2016097482,PFIZER,,45,YR,,M,Y,,,20160509,,LW,US,US,EFAVIRENZ,Asthenia;Cerebrovascular accident;Tremor,120830542,DS,,,120830542,1,20090408,201504,,,120830542,1,Hormone replacement therapy
12101719,121017194,4,F,20160113,20160405,20160222,20160414,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-010797,BRISTOL MYERS SQUIBB,,56,YR,,F,Y,55,KG,20160414,,OT,UG,UG,EFAVIRENZ,Colporrhaphy;Urinary tract infection,121017194,HO,,,121017194,1,20121115,,,,121017194,1,HIV infection
12110219,121102193,3,F,,20160329,20160224,20160407,EXP,,DE-GILEAD-2016-0199102,GILEAD,,46,YR,A,M,Y,80,KG,20160407,,CN,DE,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Depression;Drug ineffective;Dysphoria;Treatment noncompliance;Viral mutation identified;Weight increased,121102193,OT,,,121102193,2,201402,,,,121102193,1,Product used for unknown indication
12117436,121174362,2,F,,20160418,20160225,20160426,EXP,,ZA-GILEAD-2016-0199644,GILEAD,,47,YR,A,F,Y,114.8,KG,20160426,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Metastases to liver,121174362,DE,,,121174362,1,20111024,,,,121174362,1,HIV infection
12123141,121231412,2,F,201406,20160510,20160227,20160513,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-012812,BRISTOL MYERS SQUIBB,,41,YR,,M,Y,,,20160513,,OT,GB,GB,SUSTIVA,Gastrostomy,121231412,OT,,,121231412,1,2012,,,,121231412,1,HIV infection
12144212,121442123,3,F,20151221,20160608,20160304,20160615,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-014561,BRISTOL MYERS SQUIBB,,49,YR,,M,Y,,,20160615,,CN,GB,GB,SUSTIVA,Ankle fracture;Ankle operation;Road traffic accident,121442123,HO,,,,,,,,,121442123,1,Product used for unknown indication
12160761,121607615,5,F,201602,20160611,20160308,20160616,EXP,,BR-GILEAD-2016-0201948,GILEAD,,49,YR,A,M,Y,68,KG,20160616,,OT,BR,BR,EFAVIRENZ,Hepatic failure;Multiple organ dysfunction syndrome,121607615,DE,,,121607615,1,20151017,20160219,,,121607615,1,HIV infection
12170478,121704782,2,F,,20160510,20160311,20160511,EXP,,TH-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-016764,BRISTOL MYERS SQUIBB,,,,,,Y,,,20160511,,OT,TH,TH,EFAVIRENZ,Drug interaction;Ergot poisoning;Off label use,121704782,OT,,,,,,,,,121704782,1,HIV infection
12174737,121747373,3,F,,20160407,20160314,20160503,EXP,,JP-ROCHE-1724544,ROCHE,"ENDO Y, HAYASHI S, OHSAWA Y, IMAMURA J AND KIMURA K PEGYLATED INTERFERON FOR THE TREATMENT OF CHRONIC HEPATITIS C WITH HIV-INFECTED PATIENTS. KANZO 2016 JAN;57 (1):34-41.",42,YR,,M,Y,,,20160503,,MD,JP,JP,EFAVIRENZ,Lactic acidosis;Nausea;Vomiting,121747373,OT,,,,,,,,,121747373,1,Hepatitis C
12188434,121884347,7,F,20160229,20160606,20160317,20160614,EXP,,ZW-GILEAD-2016-0203612,GILEAD,,39,YR,A,M,Y,61.5,KG,20160614,,OT,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Alopecia;Anaemia;Gastroenteritis;Hyponatraemia;Tuberculosis;Weight decreased,121884347,OT,,,121884347,1,20160219,20160228,,,121884347,1,Kaposi's sarcoma AIDS related
12188459,121884592,2,F,,20160401,20160317,20160407,EXP,,DE-GILEAD-2016-0199098,GILEAD,,46,YR,A,M,Y,82,KG,20160407,,CN,DE,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Psoriasis,121884592,OT,,,121884592,1,200812,,,,121884592,1,HIV infection
12190227,121902272,2,F,,20160402,20160318,20160415,EXP,,US-CIPLA LTD.-2016US02523,CIPLA,"RAHANGDALE L, CATES J, POTTER J, BADELL ML, SEIDMAN D, MILLER ES ET AL.,. INTEGRASE INHIBITORS IN LATE PREGNANCY AND RAPID HIV VIRAL LOAD REDUCTION. AMERICAN JOURNAL OF OBSTETRICS + GYNECOLOGY. 2016;214:385.E1 TO E7",,,,,Y,,,20160415,,MD,US,US,Efavirenz,Foetal exposure during pregnancy;Group B streptococcus neonatal sepsis,121902272,OT,,,,,,,,,,,
12190308,121903082,2,F,,20160402,20160318,20160415,EXP,,US-CIPLA LTD.-2016US02525,CIPLA,"RAHANGDALE L, CATES J, POTTER J, BADELL ML, SEIDMAN D, MILLER ES ET AL.,. INTEGRASE INHIBITORS IN LATE PREGNANCY AND RAPID HIV VIRAL LOAD REDUCTION. AMERICAN JOURNAL OF OBSTETRICS + GYNECOLOGY. 2016;214:385.E1 TO E7",,,,,Y,,,20160415,,MD,US,US,Efavirenz,Foetal exposure during pregnancy;Respiratory syncytial virus infection,121903082,OT,,,,,,,,,,,
12213424,122134242,2,F,20160324,20160331,20160328,20160401,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-022994,BRISTOL MYERS SQUIBB,,31,YR,,F,Y,,,20160401,,OT,MW,MW,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Neutropenia,122134242,OT,,,122134242,1,20151216,20160309,,,122134242,1,Acquired immunodeficiency syndrome
12215305,122153052,2,F,20150828,20160330,20160328,20160404,EXP,,ZA-BMSGILMSD-2016-0205223,GILEAD,,26,YR,A,F,Y,,,20160404,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,122153052,OT,,,122153052,1,20150302,,,,122153052,1,HIV infection
12217103,122171032,2,F,,20160331,20160329,20160405,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-022052,BRISTOL MYERS SQUIBB,,65,YR,,M,Y,,,20160405,,CN,GB,GB,EFAVIRENZ,Death,122171032,DE,,,,,,,,,122171032,1,Product used for unknown indication
12219877,122198772,2,F,,20160330,20160330,20160405,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-022474,BRISTOL MYERS SQUIBB,,43,YR,,M,Y,,,20160405,,CN,GB,GB,EFAVIRENZ,Cerebrovascular accident;Cognitive disorder;Depression;Fatigue;Hypokinesia;Intentional self-injury,122198772,OT,,,,,,,,,122198772,1,Product used for unknown indication
12223186,122231862,2,F,20160323,20160411,20160330,20160414,EXP,,MW-GILEAD-2016-0205855,GILEAD,,34,YR,A,M,Y,,,20160414,,OT,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bacterial sepsis;Malaria,122231862,OT,,,122231862,1,20150325,20160322,,,122231862,1,Kaposi's sarcoma AIDS related
12223673,122236732,2,F,2012,20160401,20160330,20160411,EXP,,GB-MYLANLABS-2016M1012317,MYLAN,,,,,,Y,,,20160411,,CN,GB,GB,EFAVIRENZ,Cerebrovascular accident;Cognitive disorder;Depression;Fatigue;Hypokinesia;Intentional self-injury,122236732,OT,,,,,,,,,122236732,1,Product used for unknown indication
12232526,122325261,1,I,201603,20160329,20160401,20160401,EXP,,US-BAUSCH-BL-2016-007603,BAUSCH AND LOMB,,70,YR,,M,Y,,,20160401,,CN,US,US,EFAVIRENZ;SUSTIVA,Hospitalisation,122325261,HO,,,122325261,1,201501,,,,122325261,1,Product used for unknown indication
12233400,122334001,1,I,20100218,20160322,20160404,20160404,EXP,,UA-CIPLA LTD.-2016UA03161,CIPLA,,,,,,Y,,,20160404,,,UA,UA,Efavirenz,Anaemia;Asthenia;Lactic acidosis;Leukopenia;Pallor;Renal failure,122334001,LT,,,122334001,1,20100210,,,,122334001,1,HIV infection
12233409,122334091,1,I,20111017,20160322,20160404,20160404,EXP,,UA-CIPLA LTD.-2016UA03167,CIPLA,,,,,,Y,,,20160404,,,UA,UA,Efavirenz,Renal failure,122334091,LT,,,122334091,1,20101104,,,,122334091,1,HIV infection
12233580,122335801,1,I,20080101,,20160401,20160401,DIR,,,,,46,YR,,M,N,,,20160331,N,OT,US,,SUSTIVA,Abnormal dreams,,,122335801,HP,,,,,,,,,
12234046,122340461,1,I,20090723,20160322,20160404,20160404,EXP,,UA-CIPLA LTD.-2016UA03212,CIPLA,,,,,,Y,,,20160404,,,UA,UA,Efavirenz,Anaemia,122340461,DS,,,122340461,1,20090328,,,,122340461,1,HIV infection
12236810,122368101,1,I,20100120,20160322,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03173,CIPLA,,,,,,Y,,,20160405,,,UA,UA,Efavirenz,Anaemia,122368101,DS,,,122368101,1,20091212,,,,122368101,1,Antiretroviral therapy
12236814,122368141,1,I,20091016,20160322,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03191,CIPLA,,,,,,Y,,,20160405,,,UA,UA,Efavirenz,Asthenia;Dyspnoea,122368141,DS,,,122368141,1,20090701,,,,122368141,1,HIV infection
12236815,122368151,1,I,20090909,20160322,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03197,CIPLA,,,,,,Y,,,20160405,,,UA,UA,Efavirenz,Leukopenia,122368151,DS,,,122368151,1,20090328,,,,122368151,1,HIV infection
12236816,122368161,1,I,20091001,20160322,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03190,CIPLA,,,,,,Y,,,20160405,,,UA,UA,Efavirenz,Asthenia;Dyspnoea,122368161,DS,,,122368161,1,20090120,,,,122368161,1,HIV infection
12236829,122368291,1,I,20100121,20160322,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03179,CIPLA,,,,,,Y,,,20160405,,,UA,UA,Efavirenz,Anaemia,122368291,HO,,,122368291,1,20080605,,,,122368291,1,HIV infection
12236831,122368311,1,I,20100120,20160322,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03168,CIPLA,,,,,,Y,,,20160405,,,UA,UA,Efavirenz,Anaemia,122368311,HO,,,122368311,1,20091119,,,,122368311,1,HIV infection
12236847,122368471,1,I,20090101,20160322,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03210,CIPLA,,,,,,Y,,,20160405,,,UA,UA,Efavirenz,Aggression;Mood swings;Pruritus;Sleep disorder;Tearfulness,122368471,OT,,,122368471,1,20081020,,,,122368471,1,HIV infection
12236848,122368481,1,I,20090714,20160322,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03215,CIPLA,,,,,,Y,,,20160405,,,UA,UA,Efavirenz,Dizziness;Headache;Lethargy;Somnolence,122368481,DS,,,122368481,1,20070116,,,,122368481,1,HIV infection
12236851,122368511,1,I,20081229,20160322,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03203,CIPLA,,,,,,Y,,,20160405,,,UA,UA,Efavirenz,Dizziness;Gait disturbance;Insomnia,122368511,DS,,,122368511,1,20060412,,,,122368511,1,HIV infection
12236854,122368541,1,I,20081208,20160322,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03206,CIPLA,,,,,,Y,,,20160405,,,UA,UA,Efavirenz,Coordination abnormal;Disturbance in attention;Dizziness;Memory impairment;Tremor,122368541,HO,,,122368541,1,20081206,,,,122368541,1,Antiretroviral therapy
12236856,122368561,1,I,20090223,20160322,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03207,CIPLA,,,,,,Y,,,20160405,,,UA,UA,Efavirenz,Dizziness;Somnolence;Yawning,122368561,HO,,,122368561,1,20081206,,,,122368561,1,HIV infection
12236875,122368751,1,I,20090815,20160322,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03219,CIPLA,,,,,,Y,,,20160405,,,UA,UA,Efavirenz,Anaemia;Asthenia;Decreased appetite;Dizziness;Nausea;Tachycardia,122368751,DS,,,122368751,1,20090806,,,,122368751,1,HIV infection
12236953,122369531,1,I,20120329,20160322,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03252,CIPLA,,,,,,Y,,,20160405,,,UA,UA,Efavirenz,Anaemia,122369531,HO,,,122369531,1,20111223,,,,122369531,1,HIV infection
12237035,122370351,1,I,20090806,20160322,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03222,CIPLA,,,,,,Y,,,20160405,,,UA,UA,Efavirenz,Anaemia;Asthenia;Decreased appetite;Dizziness;Nausea;Tachycardia,122370351,HO,,,122370351,1,20090806,,,,122370351,1,HIV infection
12237089,122370891,1,I,20090413,20160322,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03242,CIPLA,,,,,,Y,,,20160405,,,UA,UA,Efavirenz,Anaemia,122370891,HO,,,122370891,1,20090114,,,,122370891,1,HIV infection
12237092,122370921,1,I,20090803,20160322,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03230,CIPLA,,,,,,Y,,,20160405,,,UA,UA,Efavirenz,Anaemia,122370921,HO,,,122370921,1,20090608,,,,122370921,1,HIV infection
12237098,122370981,1,I,20090617,20160322,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03235,CIPLA,,,,,,Y,,,20160405,,,UA,UA,Efavirenz,Anaemia;Leukopenia;Neutropenia,122370981,LT,,,122370981,1,20080521,,,,122370981,1,HIV infection
12237108,122371081,1,I,20090217,20160322,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03244,CIPLA,,,,,,Y,,,20160405,,,UA,UA,Efavirenz,Anaemia,122371081,HO,,,122371081,1,20081017,,,,122371081,1,HIV infection CDC Group IV subgroup E
12237113,122371131,1,I,,20160322,20160405,20160405,EXP,,GB-HETERO LABS LTD-1050207,HETERO,,65,YR,,M,Y,,,20160405,,OT,GB,GB,Efavirenz,Death,122371131,DE,,,,,,,,,122371131,1,Product used for unknown indication
12237148,122371481,1,I,20090624,20160322,20160405,20160405,EXP,,UA-CIPLA LTD.-2016UA03251,CIPLA,,,,,,Y,,,20160405,,,UA,UA,Efavirenz,Anaemia;Asthenia;Dizziness;Leukopenia,122371481,LT,,,122371481,1,20090527,,,,122371481,1,HIV infection
12237261,122372613,3,F,2015,20160530,20160405,20160606,EXP,,US-ENDO PHARMACEUTICALS INC.-2016-002250,ENDO,,,,,M,Y,113.5,KG,20160606,,CN,US,US,SUSTIVA,Chronic obstructive pulmonary disease;Drug dose omission;Drug ineffective;Paralysis;Weight increased,122372613,HO,,,122372613,1,201502,201506,,,122372613,1,Pain in extremity
12237989,122379892,2,F,,20160331,20160405,20160510,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2016GSK044584,VIIV,,,,,F,Y,,,20160510,,CN,GB,GB,SUSTIVA,Death,122379892,DE,,,,,,,,,122379892,1,Product used for unknown indication
12238174,122381742,2,F,,20160331,20160405,20160511,EXP,,GB-GLAXOSMITHKLINE-GB2016GSK044584,GLAXOSMITHKLINE,,,,,F,Y,,,20160511,,CN,GB,GB,SUSTIVA,Death,122381742,OT,,,,,,,,,122381742,1,Product used for unknown indication
12239382,122393821,1,I,20150721,20160330,20160405,20160405,EXP,,US-BMSGILMSD-2016-0206544,GILEAD,,37,YR,A,F,Y,,,20160405,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,122393821,OT,,,,,,,,,122393821,1,HIV infection
12239484,122394843,3,F,,20160523,20160405,20160531,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-025492,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20160531,,CN,GB,GB,SUSTIVA,Death,122394843,DE,,,122394843,1,,201603,,,122394843,1,Product used for unknown indication
12240484,122404841,1,I,,20160328,20160405,20160405,EXP,,US-GILEAD-2016-0206026,GILEAD,,57,YR,A,F,Y,,,20160405,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cardiac failure;Renal impairment,122404841,OT,,,,,,,,,122404841,1,HIV infection
12240693,122406932,2,F,,20160422,20160406,20160426,EXP,,US-009507513-1603USA013451,MERCK,,,,,M,Y,,,20160426,,PH,US,US,SUSTIVA,Cardiac disorder,122406932,HO,,,,,,,,,122406932,1,HIV infection
12242834,122428341,1,I,,20160330,20160406,20160406,EXP,,US-GILEAD-2016-0206511,GILEAD,,52,YR,A,M,Y,,,20160406,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Malaise;T-lymphocyte count decreased,122428341,HO,,,122428341,1,2000,,,,122428341,1,HIV infection
12243877,122438772,2,F,20160328,20160413,20160406,20160419,EXP,,ZW-GILEAD-2016-0206751,GILEAD,,54,YR,A,M,Y,,,20160419,,OT,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Kaposi's sarcoma,122438772,DE,,,122438772,1,20150715,20160327,,,122438772,1,Kaposi's sarcoma AIDS related
12246116,122461161,1,I,,20160404,20160407,20160407,EXP,,CA-ABBVIE-16P-028-1598884-00,ABBVIE,,54,YR,,M,Y,,,20160407,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,122461161,OT,,,,,,,,,122461161,1,Product used for unknown indication
12246986,122469861,1,I,20150527,20150601,20160407,20160407,EXP,,RO-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-038163,BRISTOL MYERS SQUIBB,,31,YR,,M,Y,64,KG,20160407,,OT,RO,RO,BLINDED EFAVIRENZ,Hepatitis C;Hepatitis toxic,122469861,HO,,,122469861,1,20140403,20150530,,,122469861,1,HIV infection
12247223,122472232,2,F,20151214,20160415,20160407,20160419,EXP,,US-BMSGILMSD-2016-0206961,GILEAD,,41,YR,A,M,Y,58.96,KG,20160419,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Ischaemic stroke,122472232,OT,,,122472232,1,2009,,,,122472232,1,HIV infection
12248775,122487751,1,I,20151019,20160401,20160408,20160408,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-026515,BRISTOL MYERS SQUIBB,,30,YR,,F,Y,47,KG,20160408,,CN,CN,CN,EFAVIRENZ,Hepatic function abnormal,122487751,LT,,,122487751,1,20150513,20151110,,,122487751,1,Acquired immunodeficiency syndrome
12249622,122496221,1,I,20150715,20160401,20160408,20160408,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-026563,BRISTOL MYERS SQUIBB,,26,YR,,M,Y,,,20160408,,CN,CN,CN,EFAVIRENZ,Lung infection,122496221,HO,,,122496221,1,20150428,20150728,,,122496221,1,Acquired immunodeficiency syndrome
12251998,122519981,1,I,,20160328,20160411,20160411,EXP,,US-CIPLA LTD.-2016ZA03391,CIPLA,"HOFFMANN CJ, FIELDING KL, CHARALAMBOUS S, SULKOWSKI MS, INNES C, THIO CL ET AL.,. ANTIRETROVIRAL THERAPY USING ZIDOVUDINE, LAMIVUDINE, AND EFAVIRENZ IN SOUTH AFRICA: TOLERABILITY AND CLINICAL EVENTS. AIDS. 2008;22 (1):67 TO 74",,,,,Y,,,20160411,,OT,US,ZA,Efavirenz,Adverse event;Death,122519981,OT,,,,,,,,,122519981,1,Antiretroviral therapy
12252035,122520351,1,I,,20160328,20160411,20160411,EXP,,US-CIPLA LTD.-2016ZA03392,CIPLA,"HOFFMANN CJ, FIELDING KL, CHARALAMBOUS S, SULKOWSKI MS, INNES C, THIO CL ET AL.,. ANTIRETROVIRAL THERAPY USING ZIDOVUDINE, LAMIVUDINE, AND EFAVIRENZ IN SOUTH AFRICA: TOLERABILITY AND CLINICAL EVENTS. AIDS. 2008;22 (1):67 TO 74",,,,,Y,,,20160411,,OT,US,ZA,Efavirenz,Neutropenia;Pneumonia,122520351,OT,,,,,,,,,122520351,1,Antiretroviral therapy
12252042,122520421,1,I,,20160328,20160411,20160411,EXP,,US-CIPLA LTD.-2016ZA03427,CIPLA,"HOFFMANN CJ, FIELDING KL, CHARALAMBOUS S, SULKOWSKI MS, INNES C, THIO CL ET AL.,. ANTIRETROVIRAL THERAPY USING ZIDOVUDINE, LAMIVUDINE, AND EFAVIRENZ IN SOUTH AFRICA: TOLERABILITY AND CLINICAL EVENTS. AIDS. 2008;22 (1):67 TO 74",,,,,Y,,,20160411,,OT,US,ZA,Efavirenz,Extrapulmonary tuberculosis;HIV infection;Neutropenia,122520421,DE,,,,,,,,,122520421,1,Antiretroviral therapy
12252151,122521511,1,I,,20160404,20160411,20160411,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-025384,BRISTOL MYERS SQUIBB,,63,YR,,M,Y,,,20160411,,CN,GB,GB,SUSTIVA,Lower respiratory tract infection,122521511,OT,,,,,,,,,122521511,1,Product used for unknown indication
12252299,122522991,1,I,20151022,20160401,20160411,20160411,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-026647,BRISTOL MYERS SQUIBB,,30,YR,,F,Y,76,KG,20160411,,CN,CN,CN,EFAVIRENZ,Neurotoxicity,122522991,OT,,,122522991,1,20120101,20151022,,,122522991,1,HIV infection
12252364,122523641,1,I,20151123,20160401,20160411,20160411,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-026519,BRISTOL MYERS SQUIBB,,50,YR,,M,Y,62,KG,20160411,,CN,CN,CN,EFAVIRENZ,Dermatitis,122523641,HO,,,122523641,1,20151014,20151123,,,122523641,1,Acquired immunodeficiency syndrome
12253502,122535021,1,I,20160329,20160405,20160411,20160411,EXP,,US-GILEAD-2016-0207534,GILEAD,,,,,,Y,,,20160411,,OT,US,US,EFAVIRENZ,Ultrasound antenatal screen abnormal,122535021,CA,,,122535021,1,20160202,20160201,,,122535021,1,HIV infection
12256592,122565921,1,I,20160329,20160405,20160412,20160412,EXP,,US-VIIV HEALTHCARE LIMITED-US2016048464,VIIV,,,,,,Y,,,20160412,,OT,US,US,Efavirenz,Ultrasound antenatal screen abnormal,122565921,CA,,,122565921,1,20160202,20160201,,,122565921,1,HIV infection
12256882,122568821,1,I,20160329,20160405,20160412,20160412,EXP,,US-GLAXOSMITHKLINE-US2016048464,GLAXOSMITHKLINE,,,,,,Y,,,20160412,,OT,US,US,Efavirenz,Ultrasound antenatal screen abnormal,122568821,CA,,,122568821,1,20160202,20160201,,,122568821,1,HIV infection
12262224,122622241,1,I,20151106,20160401,20160413,20160413,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-026669,BRISTOL MYERS SQUIBB,,39,YR,,F,Y,60,KG,20160413,,CN,CN,CN,EFAVIRENZ,Fall;Tibia fracture,122622241,HO,,,122622241,1,20151010,20151123,,,122622241,1,HIV infection
12262651,122626511,1,I,20151202,20160401,20160413,20160413,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-026673,BRISTOL MYERS SQUIBB,,33,YR,,F,Y,57,KG,20160413,,CN,CN,CN,EFAVIRENZ,Hepatic function abnormal,122626511,LT,,,122626511,1,20151102,20151203,,,122626511,1,HIV infection
12265780,122657801,1,I,20160214,20160226,20160413,20160413,EXP,,ES-BAXALTA-2016BLT001295,BAXALTA,,52,YR,,M,Y,,,20160413,,MD,ES,ES,EFAVIRENZ,Diarrhoea;Renal failure,122657801,HO,,,122657801,1,20160212,,,,122657801,1,Factor VIII deficiency
12266073,122660731,1,I,,20160408,20160413,20160413,EXP,,US-BMSGILMSD-2016-0207958,GILEAD,,34,YR,A,M,Y,,,20160413,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Fatigue;Fear;Feeling abnormal;Intentional product use issue;Malaise;Nasopharyngitis,122660731,HO,,,,,,,,,122660731,1,HIV infection
12269160,122691601,1,I,20061107,20160126,20160414,20160414,EXP,,TH-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-006624,BRISTOL MYERS SQUIBB,,5,YR,,M,Y,14,KG,20160414,,OT,TH,TH,EFAVIRENZ,Hepatitis;Hypoglycaemia;Virologic failure,122691601,HO,,,122691601,4,20060417,20061108,,,122691601,1,HIV infection
12269815,122698151,1,I,,20160404,20160415,20160415,EXP,,US-CIPLA LTD.-2016US03674,CIPLA,"JAO J, ABRAMS EJ, PHILLIPS T, PETRO G, ZERBE A, MYER L. IN UTERO TENOFOVIR EXPOSURE IS NOT ASSOCIATED WITH FETAL LONG BONE GROWTH. CLINICAL INFECTIOUS DISEASES. 2016;1 TO 17",,,,,Y,,,20160415,,MD,US,ZA,Efavirenz,Foetal exposure during pregnancy;Growth retardation,122698151,OT,,,,,,,,,,,
12272300,122723001,1,I,20151207,20160401,20160415,20160415,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-026657,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,59,KG,20160415,,CN,CN,CN,EFAVIRENZ,Dermatitis allergic,122723001,OT,,,122723001,1,20151201,20151211,,,122723001,1,HIV infection
12272745,122727454,4,F,201505,20160627,20160415,20160629,PER,,US-PFIZER INC-2016213788,PFIZER,,60,YR,,M,Y,72.57,KG,20160629,,OT,US,US,SUSTIVA,Atrial fibrillation;Drug prescribing error;Palpitations,122727454,HO,,,122727454,1,201505,201505,,,122727454,1,Smoking cessation therapy
12274736,122747362,2,F,2006,20160414,20160415,20160420,EXP,,US-BMSGILMSD-2016-0208708,GILEAD,,56,YR,A,F,Y,,,20160420,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Colorectal cancer;Colostomy,122747362,OT,,,,,,,,,122747362,1,HIV infection
12276216,122762161,1,I,,20160408,20160418,20160418,EXP,GB-MHRA-EYC 00137699,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-027244,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20160418,,CN,GB,GB,SUSTIVA,Sleep disorder,122762161,OT,,,,,,,,,122762161,1,Product used for unknown indication
12276875,122768751,1,I,,20160408,20160418,20160418,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-027815,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20160418,,CN,GB,GB,EFAVIRENZ,Sleep disorder,122768751,OT,,,,,,,,,122768751,1,Product used for unknown indication
12282756,122827562,2,F,20150910,20160506,20160419,20160511,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-029139,BRISTOL MYERS SQUIBB,,52,YR,,M,Y,46.5,KG,20160511,,CN,CN,CN,EFAVIRENZ,Liver injury,122827562,OT,,,122827562,1,20150501,20150910,,,122827562,1,Acquired immunodeficiency syndrome
12283361,122833613,3,F,20160411,20160421,20160419,20160428,EXP,,MW-GILEAD-2016-0209071,GILEAD,,30,YR,A,M,Y,,,20160428,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Kaposi's sarcoma,122833613,DE,,,122833613,1,20150612,20160410,,,122833613,1,Acquired immunodeficiency syndrome
12283997,122839972,2,F,20160115,20160511,20160419,20160520,EXP,,US-GILEAD-2016-0203642,GILEAD,,65,YR,E,M,Y,,,20160520,,MD,US,US,SUSTIVA,Acute kidney injury;Drug interaction;Rhabdomyolysis,122839972,OT,,,122839972,1,201601,201601,,,122839972,1,HIV infection
12285015,122850152,2,F,20060712,20160427,20160420,20160503,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-14230114,BRISTOL MYERS SQUIBB,,33,YR,,M,Y,,,20160503,,CN,JP,JP,EFAVIRENZ,Diabetes mellitus;Oesophageal varices haemorrhage,122850152,DE,,,122850152,1,20040629,20110401,,,122850152,1,HIV infection
12285931,122859311,1,I,,20150422,20160420,20160420,EXP,,GB-009507513-1505GBR001885,MERCK,,39,YR,,F,Y,,,20160420,,CN,UA,GB,EFAVIRENZ,Aplasia pure red cell;Maternal exposure during pregnancy;Off label use,122859311,OT,,,,,,,,,122859311,1,HIV infection
12286803,122868031,1,I,,20160408,20160420,20160420,EXP,,"ZA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-23565BI",BOEHRINGER INGELHEIM,"DENTI P,MARTINSON N,COHN S,MASHABELA F,HOFFMANN J,MSANDIWA R,ET AL. POPULATION PHARMACOKINETICS OF RIFAMPIN IN PREGNANT WOMEN WITH TUBERCULOSIS AND HIV COINFECTION IN SOWETO, SOUTH AFRICA. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 2016;60:3:1234-1241.",,,,F,Y,,,20160420,,OT,COUNTRY NOT SPECIFIED,ZA,EFAVIRENZ,Haemorrhage in pregnancy,122868031,OT,,,,,,,,,122868031,1,HIV infection
12287827,122878271,1,I,,20160408,20160420,20160420,EXP,GB-MHRA-EYC 00137699,GB-MYLANLABS-2016M1015047,MYLAN,,,,,,Y,,,20160420,,PH,GB,GB,EFAVIRENZ,Sleep disorder,122878271,OT,,,,,,,,,,,
12300264,123002641,1,I,20060420,20160416,20160425,20160425,EXP,,IT-SA-2016SA078964,AVENTIS,,42,YR,A,M,Y,55,KG,20160425,,PH,IT,IT,SUSTIVA,Arthralgia;Musculoskeletal pain,123002641,OT,,,123002641,1,20060318,20061110,,,123002641,1,Pulmonary tuberculosis
12300436,123004361,1,I,,20160420,20160425,20160425,EXP,,GB-GILEAD-2016-0209655,GILEAD,,47,YR,A,M,Y,,,20160425,,PH,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,123004361,DE,,,,,,,,,123004361,1,HIV infection
12308286,123082862,2,F,20160202,20160525,20160426,20160601,EXP,,UG-GILEAD-2016-0210345,GILEAD,,56,YR,A,F,Y,65,KG,20160601,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Radius fracture;Ulna fracture,123082862,DS,,,123082862,1,20150709,,,,123082862,1,HIV infection
12308409,123084091,1,I,,20160419,20160426,20160426,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-031023,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20160426,,CN,US,US,SUSTIVA,Death,123084091,OT,,,123084091,1,20150513,,,,123084091,1,HIV infection
12311657,123116571,1,I,2016,20160121,20160427,20160427,EXP,,US-BMSGILMSD-2016-0194875,GILEAD,,35,YR,A,M,Y,92.97,KG,20160427,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteopenia;Renal impairment,123116571,OT,,,,,,,,,123116571,1,HIV infection
12315390,123153901,1,I,2015,20150807,20160428,20160428,PER,,US-JAZZ-2015-US-011775,JAZZ,,,,,M,Y,,,20160428,,,US,US,Efavirenz,Nasopharyngitis,,,,,123153901,1,201507,201507,,,123153901,1,Narcolepsy
12315986,123159861,1,I,,20160418,20160428,20160428,EXP,,US-BMSGILMSD-2016-0209425,GILEAD,,46,YR,A,M,Y,,,20160428,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Malaise;Weight decreased,123159861,OT,,,,,,,,,123159861,1,Product used for unknown indication
12316015,123160152,2,F,,20151215,20160428,20160505,EXP,,IT-GILEAD-2016-0211234,GILEAD,,43,YR,A,M,Y,,,20160505,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Chronic kidney disease;Psychiatric symptom,123160152,OT,,,123160152,2,2011,2011,,,123160152,1,Product used for unknown indication
12320551,123205512,2,F,,20160505,20160429,20160510,EXP,,IT-GILEAD-2016-0211232,GILEAD,,66,YR,E,M,Y,,,20160510,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Chronic kidney disease;Hypertension,123205512,OT,,,123205512,1,2012,,,,123205512,1,HIV infection
12320560,123205602,2,F,,20160501,20160429,20160509,EXP,,IT-GILEAD-2016-0211196,GILEAD,,62,YR,A,F,Y,,,20160509,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Chronic kidney disease;Osteoporosis,123205602,OT,,,123205602,1,2010,,,,123205602,1,Product used for unknown indication
12320561,123205612,2,F,,20160501,20160429,20160505,EXP,,IT-GILEAD-2016-0211206,GILEAD,,55,YR,A,M,Y,,,20160505,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Chronic kidney disease,123205612,OT,,,123205612,3,2009,,,,123205612,1,Product used for unknown indication
12325357,123253572,2,F,,20160523,20160502,20160526,EXP,,US-BMSGILMSD-2016-0211538,GILEAD,,54,YR,A,M,Y,,,20160526,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Plasma cell myeloma,123253572,OT,,,123253572,1,20110428,,,,123253572,1,HIV infection
12326313,123263131,1,I,20130108,20160426,20160503,20160503,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-032890,BRISTOL MYERS SQUIBB,,69,YR,,M,Y,,,20160503,,OT,US,US,SUSTIVA,Anaphylactic reaction;Rash,123263131,OT,,,,,,,,,123263131,1,Product used for unknown indication
12333631,123336311,1,I,20160428,20160428,20160504,20160504,EXP,,PT-GILEAD-2016-0211643,GILEAD,,42,YR,A,M,Y,,,20160504,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction,123336311,OT,,,123336311,1,20160411,,,,123336311,1,Hepatitis C
12335445,123354452,2,F,20160127,20160426,20160504,20160511,EXP,,ZW-GILEAD-2016-0211545,GILEAD,,28,YR,A,M,Y,69.9,KG,20160511,,OT,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Kaposi's sarcoma,123354452,OT,,,123354452,1,20150702,20160407,,,123354452,1,Acquired immunodeficiency syndrome
12338207,123382072,2,F,,20160505,20160505,20160513,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-031517,BRISTOL MYERS SQUIBB,,65,YR,,M,Y,,,20160513,,OT,US,US,EFAVIRENZ,Calculus urinary,123382072,OT,,,,,,,,,123382072,1,HIV infection
12340054,123400541,1,I,,20160421,20160506,20160506,EXP,,US-CIPLA LTD.-2016US04480,CIPLA,"EL-MALLAWANY NK, KAMIYANGO W, SLONE JS, VILLIERA J, KOVARIK CL, COX CM ET AL.,. CLINICAL FACTORS ASSOCIATED WITH LONG-TERM COMPLETE REMISSION VERSUS POOR RESPONSE TO CHEMOTHERAPY IN HIV-INFECTED CHILDREN AND ADOLESCENTS WITH KAPOSI SARCOMA RECEIVING BLEOMYCIN AND VINCRISTINE: A RETROSPECTIVE OBSERVATIONAL STUDY. PLOS ONE. 2016;1 TO 17",,,,,Y,,,20160506,,OT,US,MW,Efavirenz,Neuropathy peripheral,123400541,OT,,,,,,,,,123400541,1,HIV infection
12340110,123401101,1,I,,20160421,20160506,20160506,EXP,,US-CIPLA LTD.-2016US04483,CIPLA,"EL-MALLAWANY NK, KAMIYANGO W, SLONE JS, VILLIERA J, KOVARIK CL, COX CM ET AL.,. CLINICAL FACTORS ASSOCIATED WITH LONG-TERM COMPLETE REMISSION VERSUS POOR RESPONSE TO CHEMOTHERAPY IN HIV-INFECTED CHILDREN AND ADOLESCENTS WITH KAPOSI SARCOMA RECEIVING BLEOMYCIN AND VINCRISTINE: A RETROSPECTIVE OBSERVATIONAL STUDY. PLOS ONE. 2016;1 TO 17",,,,,Y,,,20160506,,OT,US,MW,Efavirenz,Meningitis bacterial,123401101,DE,,,,,,,,,123401101,1,HIV infection
12340116,123401161,1,I,,20160421,20160506,20160506,EXP,,US-CIPLA LTD.-2016US04481,CIPLA,"EL-MALLAWANY NK, KAMIYANGO W, SLONE JS, VILLIERA J, KOVARIK CL, COX CM ET AL.,. CLINICAL FACTORS ASSOCIATED WITH LONG-TERM COMPLETE REMISSION VERSUS POOR RESPONSE TO CHEMOTHERAPY IN HIV-INFECTED CHILDREN AND ADOLESCENTS WITH KAPOSI SARCOMA RECEIVING BLEOMYCIN AND VINCRISTINE: A RETROSPECTIVE OBSERVATIONAL STUDY. PLOS ONE. 2016;1 TO 17",,,,,Y,,,20160506,,OT,US,MW,Efavirenz,Death,123401161,DE,,,,,,,,,123401161,1,HIV infection
12340122,123401221,1,I,,20160421,20160506,20160506,EXP,,US-CIPLA LTD.-2016US04484,CIPLA,"EL-MALLAWANY NK, KAMIYANGO W, SLONE JS, VILLIERA J, KOVARIK CL, COX CM ET AL.,. CLINICAL FACTORS ASSOCIATED WITH LONG-TERM COMPLETE REMISSION VERSUS POOR RESPONSE TO CHEMOTHERAPY IN HIV-INFECTED CHILDREN AND ADOLESCENTS WITH KAPOSI SARCOMA RECEIVING BLEOMYCIN AND VINCRISTINE: A RETROSPECTIVE OBSERVATIONAL STUDY. PLOS ONE. 2016;1 TO 17",,,,,Y,,,20160506,,OT,US,MW,Efavirenz,Malnutrition,123401221,DE,,,,,,,,,123401221,1,HIV infection
12340134,123401341,1,I,,20160421,20160506,20160506,EXP,,US-CIPLA LTD.-2016US04482,CIPLA,"EL-MALLAWANY NK, KAMIYANGO W, SLONE JS, VILLIERA J, KOVARIK CL, COX CM, ET AL.,. CLINICAL FACTORS ASSOCIATED WITH LONG-TERM COMPLETE REMISSION VERSUS POOR RESPONSE TO CHEMOTHERAPY IN HIV-INFECTED CHILDREN AND ADOLESCENTS WITH KAPOSI SARCOMA RECEIVING BLEOMYCIN AND VINCRISTINE: A RETROSPECTIVE OBSERVATIONAL STUDY. PLOS ONE. 2016;1 TO 17",,,,,Y,,,20160506,,OT,US,MW,Efavirenz,Sepsis,123401341,DE,,,,,,,,,123401341,1,HIV infection
12342343,123423431,1,I,,20160309,20160506,20160506,EXP,,IT-BMSGILMSD-2016-0211604,GILEAD,,74,YR,E,M,Y,,,20160506,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Chronic kidney disease;Osteoporosis,123423431,OT,,,123423431,1,2010,,,,123423431,1,Product used for unknown indication
12343465,123434651,1,I,,20160323,20160506,20160506,EXP,,IT-GILEAD-2016-0211623,GILEAD,,50,YR,A,M,Y,,,20160506,,MD,IT,IT,EFAVIRENZ,Chronic kidney disease,123434651,OT,,,123434651,2,2015,,,,123434651,1,Product used for unknown indication
12343536,123435361,1,I,2016,20160414,20160506,20160506,EXP,,FR-GLAXOSMITHKLINE-FR2016GSK050765,GLAXOSMITHKLINE,,,,,M,Y,92,KG,20160506,,CN,FR,FR,SUSTIVA,Anxiety;Arrhythmia;Chest discomfort;Chest pain;Cough;Dyspnoea;Respiratory disorder;Sleep disorder,123435361,OT,,,123435361,1,2014,,,,123435361,1,HIV infection
12343974,123439742,2,F,201404,20160606,20160507,20160630,PER,,US-JNJFOC-20160409322,JANSSEN,,81,YR,E,F,Y,,,20160630,,CN,US,US,SUSTIVA,Gastrointestinal haemorrhage;Peptic ulcer haemorrhage,123439742,HO,,,123439742,1,20140405,20140410,,,123439742,1,Atrial fibrillation
12346372,123463721,1,I,20150526,20160425,20160509,20160509,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-032232,BRISTOL MYERS SQUIBB,,74,YR,,M,Y,111.6,KG,20160509,,OT,GB,GB,EFAVIRENZ,Chest pain;Palpitations,123463721,HO,,,123463721,2,20120410,,,,123463721,1,Product used for unknown indication
12347853,123478531,1,I,2016,20160414,20160509,20160509,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2016GSK050765,VIIV,,,,,M,Y,92,KG,20160509,,CN,FR,FR,SUSTIVA,Anxiety;Arrhythmia;Chest discomfort;Chest pain;Cough;Dyspnoea;Respiratory disorder;Sleep disorder,123478531,OT,,,123478531,1,2014,,,,123478531,1,HIV infection
12356305,123563052,2,F,,20160616,20160511,20160624,EXP,,GB-GILEAD-2016-0213060,GILEAD,,30,YR,A,M,Y,,,20160624,,MD,GB,GB,EFAVIRENZ,Decreased appetite;Osteonecrosis;Photosensitivity reaction,123563052,OT,,,,,,,,,123563052,1,HIV infection
12357192,123571921,1,I,20150503,20160504,20160511,20160511,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-036449,BRISTOL MYERS SQUIBB,,50,YR,,M,Y,,,20160511,,CN,FR,FR,SUSTIVA,Arthralgia;CREST syndrome;Portal hypertension,123571921,HO,,,123571921,1,20060216,20160112,,,123571921,1,HIV infection
12358914,123589142,2,F,,20160430,20160512,20160513,EXP,,US-CIPLA LTD.-2016US04759,CIPLA,"LENCI LT, CHIN EK, ALMEIDA DR. CENTRAL RETINAL ARTERY OCCLUSION IN A YOUNG HIV-INFECTED PATIENT ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY. RETINAL CASES + BRIEF REPORTS. 2016;1 TO 3",,,,,Y,,,20160513,,OT,US,US,Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Carotid arteriosclerosis;Carotid artery stenosis;Hypercholesterolaemia;Hypertriglyceridaemia;Retinal artery occlusion,123589142,DS,,,,,,,,,123589142,1,HIV infection
12360105,123601051,1,I,,20160505,20160512,20160512,EXP,,US-MYLANLABS-2016M1019798,MYLAN,"KHALIL C, MOHANTY MJ, KAATZ G, ABU-HAMDAN D. EFAVIRENZ-ASSOCIATED URINARY MATRIX STONE - A RARE PRESENTATION. AM-J-MED-SCI 2016;351(2):213-214.",,,,,Y,,,20160512,,MD,US,US,EFAVIRENZ,Nephrolithiasis,123601051,OT,,,,,,,,,123601051,1,HIV infection
12364175,123641752,2,F,201012,20160523,20160512,20160526,EXP,,GB-GILEAD-2016-0213104,GILEAD,,70,YR,E,M,Y,75,KG,20160526,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Chronic kidney disease;Glycosuria;Hypophosphataemia;Multiple-drug resistance;Nephropathy toxic;Proteinuria;Renal tubular disorder;Treatment failure;Viral mutation identified,123641752,OT,,,123641752,1,20131114,,,,123641752,1,HIV infection
12364243,123642431,1,I,,20160427,20160512,20160512,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-037505,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20160512,,OT,IN,IN,EFAVIRENZ,Toxic epidermal necrolysis,123642431,OT,,,,,,,,,123642431,1,Product used for unknown indication
12364537,123645372,2,F,2010,20160602,20160512,20160607,EXP,,CA-GILEAD-2016-0213217,GILEAD,,66,YR,E,M,Y,105,KG,20160607,,MD,CA,CA,EFAVIRENZ,Chronic kidney disease;Renal impairment,123645372,OT,,,123645372,1,200310,20160531,,,123645372,1,HIV infection
12365197,123651971,1,I,,20160502,20160513,20160513,EXP,,US-ROCHE-1752339,ROCHE,"WEINBERG A, FORSTERH, DAVIESJ, MCFARLAND E, PAPPASJ, KINZIEK, BARR E, PAUL S, SALBENBLATT C, SODA E, VAZQUEZ A AND LEVIN M SAFETY AND TOLERABILITY OF ANTIRETROVIRALS DURING PREGNANCY (ARTICLE ID: 867674). INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 2011;2011:-.",,,,,Y,,,20160513,,OT,US,US,EFAVIRENZ,Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Blood bilirubin increased;Foetal exposure during pregnancy;Neutropenia;Sepsis;Small for dates baby;Thrombocytopenia,123651971,DE,,,,,,,,,123651971,1,Product used for unknown indication
12366602,123666021,1,I,,20160418,20160513,20160513,EXP,,NG-HETERO LABS LTD-1052115,HETERO,NATHAN YAKUBU SHEHU. A 33-YEAR-OLD PATIENT WITH HUMAN IMMUNODEFICIENCY VIRUS ON ANTIRETROVIRAL THERAPY WITH EFAVIRENZ-INDUCED COMPLEX PARTIAL SEIZURES: A CASE REPORT. JOURNAL OF MEDICAL CASE REPORTS (2016) 10:93. NIGERIA.,33,YR,,M,Y,,,20160513,,OT,NG,NG,Efavirenz,Complex partial seizures,123666021,OT,,,,,,,,,,,
12369097,123690971,1,I,20160307,20160409,20160513,20160513,EXP,,BR-HETERO LABS LTD-1052123,HETERO,,23,YR,,F,Y,,,20160513,,OT,BR,BR,EFAVIRENZ\ LAMIVUDINE \ TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Exposure during pregnancy,123690971,OT,,,123690971,1,20150817,,,,123690971,1,HIV infection
12369962,123699622,2,F,201408,20160607,20160516,20160614,EXP,,CA-GILEAD-2016-0213210,GILEAD,,62,YR,A,M,Y,81.63,KG,20160614,,MD,CA,CA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood creatinine increased;Glomerulonephritis;Nephropathy toxic;Renal impairment;Sleep disorder,123699622,OT,,,123699622,1,20160218,201602,,,123699622,1,HIV infection
12370754,123707541,1,I,,20160502,20160516,20160516,EXP,,FR-CIPLA LTD.-2016FR04930,CIPLA,,,,,,Y,,,20160516,,OT,TG,TG,Efavirenz,Drug resistance;Virologic failure,123707541,OT,,,,,,,,,123707541,1,Perinatal HIV infection
12371659,123716591,1,I,,20160419,20160516,20160516,EXP,,AU-VIIV HEALTHCARE LIMITED-AU2016GSK055049,VIIV,,75,YR,,M,Y,,,20160516,,MD,AU,AU,Efavirenz,Renal impairment,123716591,OT,,,123716591,1,20160113,,,,123716591,1,HIV infection
12371899,123718991,1,I,,20160419,20160516,20160516,EXP,,AU-GLAXOSMITHKLINE-AU2016GSK055049,GLAXOSMITHKLINE,,75,YR,,M,Y,,,20160516,,MD,AU,AU,Efavirenz,Renal impairment,123718991,OT,,,123718991,1,20160113,,,,123718991,1,HIV infection
12378500,123785002,2,F,20160426,20160527,20160517,20160607,EXP,,MZ-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-037701,BRISTOL MYERS SQUIBB,,40,YR,,F,Y,44,KG,20160607,,OT,MZ,MZ,EFAVIRENZ,Rash;Transaminases increased,123785002,OT,,,123785002,1,20160418,20160508,,,123785002,1,HIV infection
12381322,123813221,1,I,20150503,20160509,20160518,20160518,EXP,FR-AFSSAPS-TO20160894,FR-VIIV HEALTHCARE LIMITED-FR2016GSK067139,VIIV,,50,YR,,M,Y,,,20160518,,OT,FR,FR,SUSTIVA,Arthralgia;Scleroderma,123813221,OT,,,123813221,1,20060216,20160112,,,123813221,1,HIV infection
12381459,123814591,1,I,20160407,,20160517,20160517,DIR,,,,,46,YR,,F,N,41.2,KG,20160421,Y,OT,US,,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF,Blood bicarbonate decreased;Blood potassium decreased;Blood sodium increased;Cachexia;Decreased appetite;Dehydration;Diarrhoea;Gait disturbance;Haemoglobin decreased;Hypotension;Lethargy;Malaise;Pallor,123814591,DE,123814591,HP,123814591,1,20160309,20160309,,,123814591,1,Chemotherapy
12381742,123817421,1,I,20150503,20160509,20160518,20160518,EXP,FR-AFSSAPS-TO20160894,FR-GLAXOSMITHKLINE-FR2016GSK067139,GLAXOSMITHKLINE,,50,YR,,M,Y,,,20160518,,OT,FR,FR,SUSTIVA,Arthralgia;Scleroderma,123817421,OT,,,123817421,1,20060216,20160112,,,123817421,1,HIV infection
12383446,123834461,1,I,,20150615,20160518,20160518,EXP,,FR-BMSGILMSD-2016-0214004,GILEAD,,57,YR,A,M,Y,,,20160518,,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporotic fracture;Renal tubular disorder,123834461,OT,,,123834461,1,2006,,,,123834461,1,HIV infection
12384542,123845421,1,I,,20160504,20160519,20160519,EXP,,KE-SUN PHARMACEUTICAL INDUSTRIES LTD-2016R1-116734,RANBAXY,"TARUS NK, PAU AK, SERETI I, KIRUI FK, SAWE FK, AGAN BK ET AL. CHALLENGES IN MANAGEMENT OF WARFARIN ANTI-COAGULATION IN ADVANCED HIV/AIDS PATIENTS WITH VENOUS THROMBOTIC EVENTS-A CASE SERIES FROM A RESEARCH CLINIC IN RURAL KERICHO, KENYA. EAST AFRICAN MEDICAL JOURNAL. 2013;JUL^90(7):207-13",38,YR,,F,Y,,,20160519,,OT,KE,KE,Efavirenz,Deep vein thrombosis;Drug effect decreased;Drug effect increased;Drug interaction;International normalised ratio fluctuation,123845421,HO,,,,,,,,,123845421,1,HIV infection
12384549,123845491,1,I,,20160504,20160519,20160519,EXP,,KE-SUN PHARMACEUTICAL INDUSTRIES LTD-2016R1-116718,RANBAXY,"TARUS NK, PAU AK, SERETI I, KIRUI FK, SAWE FK, AGAN BK ET AL. CHALLENGES IN MANAGEMENT OF WARFARIN ANTI-COAGULATION IN ADVANCED HIV/AIDS PATIENTS WITH VENOUS THROMBOTIC EVENTS-A CASE SERIES FROM A RESEARCH CLINIC IN RURAL KERICHO, KENYA. EAST AFRICAN MEDICAL JOURNAL. 2013;JUL;90(7):207-13",39,YR,,F,Y,,,20160519,,OT,KE,KE,Efavirenz,Deep vein thrombosis;Drug effect decreased;Drug effect increased;Drug interaction;International normalised ratio fluctuation,123845491,OT,,,,,,,,,123845491,1,HIV infection
12384550,123845501,1,I,,20160411,20160519,20160519,EXP,,KE-SUN PHARMACEUTICAL INDUSTRIES LTD-2016RR-116801,RANBAXY,"TARUS NK, PAU AK, SERETI I, KIRUI FK, SAWE FK, AGAN BK, ET AL. CHALLENGES IN MANAGEMENT OF WARFARIN ANTI-COAGULATION IN ADVANCED HIV/AIDS PATIENTS WITH VENOUS THROMBOTIC EVENTS - A CASE SERIES FROM A RESEARCH CLINIC IN RURAL KERICHO, KENYA. EAST-AFR-MED-J. 2013;90 (7):207-13",30,YR,,M,Y,,,20160519,,OT,KE,KE,Efavirenz,Deep vein thrombosis;Drug interaction,123845501,OT,,,,,,,,,123845501,1,Antiretroviral therapy
12384551,123845511,1,I,,20160504,20160519,20160519,EXP,,KE-SUN PHARMACEUTICAL INDUSTRIES LTD-2016R1-116719,RANBAXY,"TARUS NK, PAU AK, SERETI I, KIRUI FK, SAWE FK, AGAN BK ET AL. CHALLENGES IN MANAGEMENT OF WARFARIN ANTI-COAGULATION IN ADVANCED HIV/AIDS PATIENTS WITH VENOUS THROMBOTIC EVENTS-A CASE SERIES FROM A RESEARCH CLINIC IN RURAL KERICHO, KENYA. EAST AFRICAN MEDICAL JOURNAL. 2013;JUL;90(7):207-13",31,YR,,M,Y,,,20160519,,OT,KE,KE,Efavirenz,Deep vein thrombosis;Drug effect decreased;Drug effect increased;Drug interaction;International normalised ratio fluctuation,123845511,OT,,,,,,,,,123845511,1,HIV infection
12384554,123845541,1,I,,20160504,20160519,20160519,EXP,,KE-SUN PHARMACEUTICAL INDUSTRIES LTD-2016R1-116736,RANBAXY,"TARUS NK, PAU AK, SERETI I, KIRUI FK, SAWE FK, AGAN BK ET AL. CHALLENGES IN MANAGEMENT OF WARFARIN ANTI-COAGULATION IN ADVANCED HIV/AIDS PATIENTS WITH VENOUS THROMBOTIC EVENTS-A CASE SERIES FROM A RESEARCH CLINIC IN RURAL KERICHO, KENYA. EAST AFRICAN MEDICAL JOURNAL. 2013;JUL;90(7):207-13",35,YR,,F,Y,,,20160519,,OT,KE,KE,Efavirenz,Deep vein thrombosis;Drug effect increased;International normalised ratio fluctuation;Potentiating drug interaction;Pulmonary embolism,123845541,OT,,,,,,,,,123845541,1,HIV infection
12384560,123845601,1,I,,20160504,20160519,20160519,EXP,,KE-SUN PHARMACEUTICAL INDUSTRIES LTD-2016R1-116717,RANBAXY,"TARUS NK, PAU AK, SERETI I, KIRUI FK, SAWE FK, AGAN BK ET AL. CHALLENGES IN MANAGEMENT OF WARFARIN ANTI-COAGULATION IN ADVANCED HIV/AIDS PATIENTS WITH VENOUS THROMBOTIC EVENTS-A CASE SERIES FROM A RESEARCH CLINIC IN RURAL KERICHO, KENYA. EAST AFRICAN MEDICAL JOURNAL. 2013;JUL;90(7):207-13",38,YR,,F,Y,,,20160519,,OT,KE,KE,Efavirenz,Deep vein thrombosis;Drug effect increased;International normalised ratio fluctuation;Potentiating drug interaction,123845601,OT,,,,,,,,,123845601,1,HIV infection
12385093,123850931,1,I,,20160504,20160519,20160519,EXP,,KE-SUN PHARMACEUTICAL INDUSTRIES LTD-2016R1-116611,RANBAXY,"TARUS NK, PAU AK, SERETI I, KIRUI FK, SAWE FK, AGAN BK ET AL. CHALLENGES IN MANAGEMENT OF WARFARIN ANTI-COAGULATION IN ADVANCED HIV/AIDS PATIENTS WITH VENOUS THROMBOTIC EVENTS-A CASE SERIES FROM A RESEARCH CLINIC IN RURAL KERICHO, KENYA. EAST AFRICAN MEDICAL JOURNAL. 2013;JUL;90(7):207-13",47,YR,,F,Y,,,20160519,,OT,KE,KE,Efavirenz,Deep vein thrombosis;Drug effect increased;Drug interaction;International normalised ratio fluctuation,123850931,HO,,,,,,,,,123850931,1,HIV infection
12387276,123872762,2,F,,20160531,20160519,20160607,EXP,,US-BMSGILMSD-2016-0214089,GILEAD,,62,YR,A,M,Y,,,20160607,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diabetes mellitus,123872762,OT,,,123872762,1,2011,,,,123872762,1,HIV infection
12392586,123925861,1,I,,20160509,20160523,20160523,EXP,,MX-CIPLA LTD.-2016CZ04938,CIPLA,,,,,,Y,,,20160523,,OT,CZ,MX,Efavirenz,Anaemia;Herpes simplex;Intracranial pressure increased;Meningioma;Rubella,123925861,HO,,,,,,,,,123925861,1,Acquired immunodeficiency syndrome
12392662,123926621,1,I,201605,,20160520,20160520,DIR,,,,,50,YR,,F,N,,,20160520,N,PH,US,,SUSTIVA,Diarrhoea;Dry skin;Urticaria,,,123926621,HP,123926621,1,20160229,,,,123926621,1,Hepatitis C
12394795,123947951,1,I,20160512,20160517,20160523,20160523,EXP,,GB-GILEAD-2016-0214430,GILEAD,,75,YR,E,M,Y,111.6,KG,20160523,,MD,GB,GB,EFAVIRENZ,Laryngeal cancer,123947951,OT,,,123947951,1,20080310,,,,123947951,1,HIV infection
12396812,123968121,1,I,20150814,20160511,20160524,20160524,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-038481,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,65.76,KG,20160524,,CN,US,US,SUSTIVA,Arthralgia;Arthritis;Depression;Drug abuse;Drug dependence;Drug withdrawal syndrome;Intentional self-injury;Joint stiffness;Ligament disorder;Suicide attempt;Tendon disorder,123968121,OT,,,,,,,,,123968121,1,Product used for unknown indication
12397040,123970401,1,I,201605,,20160523,20160523,DIR,,,,,50,YR,,F,N,,,20160520,N,PH,US,,SUSTIVA,Diarrhoea;Dry skin;Skin exfoliation;Urticaria,,,123970401,HP,123970401,1,20160229,,,,123970401,1,Hepatitis C
12399916,123999162,2,F,20160506,20160525,20160524,20160601,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-039014,BRISTOL MYERS SQUIBB,,52,YR,,F,Y,54,KG,20160601,,MD,UG,UG,EFAVIRENZ,Cardiac arrest;Electrolyte imbalance;Helicobacter infection;Malnutrition;Oesophageal squamous cell carcinoma;Oral candidiasis,123999162,OT,,,123999162,1,20120705,20160329,,,123999162,1,HIV infection
12399948,123999481,1,I,20160512,20160517,20160524,20160524,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-039008,BRISTOL MYERS SQUIBB,,75,YR,,M,Y,111.6,KG,20160524,,CN,GB,GB,EFAVIRENZ,Laryngeal cancer,123999481,OT,,,123999481,2,20120410,,,,123999481,1,Product used for unknown indication
12400325,124003251,1,I,20080501,,20160524,20160524,DIR,,,,,42,YR,,M,N,162,LBS,20160523,N,,US,,SUSTIVA,Abdominal distension;Anxiety;Condition aggravated;Decreased appetite;Depression;Fatigue;Internal haemorrhage;Rectal haemorrhage,124003251,OT,,,124003251,1,,,10,YR,124003251,1,HIV infection
12402966,124029661,1,I,,20160510,20160525,20160525,EXP,,CH-CIPLA LTD.-2016CH05075,CIPLA,,,,,,Y,,,20160525,,OT,CH,CH,Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Death,124029661,DE,,,,,,,,,124029661,1,HIV infection
12402994,124029941,1,I,,20160510,20160525,20160525,EXP,,CH-CIPLA LTD.-2016CH05076,CIPLA,,,,,,Y,,,20160525,,OT,CH,CH,Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Mental disorder,124029941,OT,,,,,,,,,124029941,1,HIV infection
12403009,124030091,1,I,,20160510,20160525,20160525,EXP,,CH-CIPLA LTD.-2016CH05109,CIPLA,,,,,,Y,,,20160525,,OT,CH,CH,Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Nephropathy toxic,124030091,OT,,,,,,,,,124030091,1,HIV infection
12403015,124030151,1,I,,20160510,20160525,20160525,EXP,,CH-CIPLA LTD.-2016CH05103,CIPLA,,,,,,Y,,,20160525,,OT,CH,CH,Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Burn oesophageal,124030151,OT,,,,,,,,,124030151,1,HIV infection
12403021,124030211,1,I,,20160510,20160525,20160525,EXP,,CH-CIPLA LTD.-2016CH05077,CIPLA,,,,,,Y,,,20160525,,OT,CH,CH,Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Drug resistance;Mental disorder;Treatment noncompliance,124030211,OT,,,,,,,,,124030211,1,HIV infection
12403041,124030411,1,I,,20160510,20160525,20160525,EXP,,CH-CIPLA LTD.-2016CH05137,CIPLA,,,,,,Y,,,20160525,,OT,CH,CH,Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Blood HIV RNA increased,124030411,OT,,,,,,,,,124030411,1,HIV infection
12403064,124030641,1,I,,20160510,20160525,20160525,EXP,,CH-CIPLA LTD.-2016CH05135,CIPLA,,,,,,Y,,,20160525,,OT,CH,CH,Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Blood HIV RNA increased,124030641,OT,,,,,,,,,124030641,1,HIV infection
12403067,124030671,1,I,,20160510,20160525,20160525,EXP,,CH-CIPLA LTD.-2016CH05110,CIPLA,,,,,,Y,,,20160525,,OT,CH,CH,Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Psychiatric decompensation,124030671,OT,,,,,,,,,124030671,1,HIV infection
12403075,124030751,1,I,,20160510,20160525,20160525,EXP,,CH-CIPLA LTD.-2016CH05136,CIPLA,,,,,,Y,,,20160525,,OT,CH,CH,Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Blood HIV RNA increased,124030751,OT,,,,,,,,,124030751,1,HIV infection
12403234,124032341,1,I,,20160510,20160525,20160525,EXP,,CH-CIPLA LTD.-2016CH05138,CIPLA,,,,,,Y,,,20160525,,OT,CH,CH,Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Blood HIV RNA increased,124032341,OT,,,,,,,,,124032341,1,HIV infection
12404284,124042841,1,I,,20160519,20160525,20160525,EXP,,GB-BMSGILMSD-2016-0215042,GILEAD,,,,A,F,Y,,,20160525,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foot fracture,124042841,HO,,,,,,,,,124042841,1,HIV infection
12408914,124089141,1,I,,20160517,20160526,20160526,EXP,,ES-VIIV HEALTHCARE LIMITED-ES2016GSK074061,VIIV,"AMBROSIONI J, COLL S, MANZARDO C, NICOLAS D, AGUERO F, BLANCO JL ET AL. VORICONAZOLE AND COBICISTAT-BOOSTED ANTIRETROVIRAL SALVAGE REGIMEN CO-ADMINISTRATION TO TREAT INVASIVE ASPERGILLOSIS IN AN HIV-INFECTED PATIENT. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2016;1125-1127",,,,M,Y,,,20160526,,OT,ES,ES,Efavirenz,Multiple-drug resistance;Pathogen resistance;Virologic failure,124089141,OT,,,,,,,,,124089141,1,HIV infection
12408942,124089421,1,I,,20160517,20160526,20160526,EXP,,ES-GLAXOSMITHKLINE-ES2016GSK074061,GLAXOSMITHKLINE,"AMBROSIONI J, COLL S, MANZARDO C, NICOLAS D, AGUERO F, BLANCO JL ET AL. VORICONAZOLE AND COBICISTAT-BOOSTED ANTIRETROVIRAL SALVAGE REGIMEN CO-ADMINISTRATION TO TREAT INVASIVE ASPERGILLOSIS IN AN HIV-INFECTED PATIENT. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2016;1125-1127",,,,M,Y,,,20160526,,OT,ES,ES,Efavirenz,Multiple-drug resistance;Pathogen resistance;Virologic failure,124089421,OT,,,,,,,,,124089421,1,HIV infection
12409468,124094681,1,I,,20160520,20160526,20160526,EXP,,US-GILEAD-2016-0215258,GILEAD,,54,YR,A,F,Y,,,20160526,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Malaise;Therapy cessation,124094681,HO,,,,,,,,,124094681,1,HIV infection
12419585,124195851,1,I,2016,20160527,20160531,20160531,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2016GSK077058,VIIV,,58,YR,,M,Y,,,20160531,,CN,FR,FR,EFAVIRENZ,Chest pain;Myocardial infarction,124195851,DE,,,124195851,1,201601,2016,,,124195851,1,HIV infection
12419841,124198411,1,I,2016,20160527,20160531,20160531,EXP,,FR-GLAXOSMITHKLINE-FR2016GSK077058,GLAXOSMITHKLINE,,58,YR,,M,Y,,,20160531,,CN,FR,FR,EFAVIRENZ,Chest pain;Myocardial infarction,124198411,OT,,,124198411,1,201601,2016,,,124198411,1,HIV infection
12423605,124236051,1,I,20160520,20160525,20160601,20160601,EXP,,TH-VIIV HEALTHCARE LIMITED-TH2016GSK076222,VIIV,,65,YR,,M,Y,,,20160601,,CN,TH,TH,EFAVIRENZ,Arthralgia;Drug reaction with eosinophilia and systemic symptoms;Myalgia;Pruritus,124236051,OT,,,124236051,1,20160504,20160523,,,124236051,1,Product used for unknown indication
12424710,124247101,1,I,20160520,20160525,20160601,20160601,EXP,,TH-GLAXOSMITHKLINE-TH2016GSK076222,GLAXOSMITHKLINE,,65,YR,,M,Y,,,20160601,,CN,TH,TH,EFAVIRENZ,Arthralgia;Drug reaction with eosinophilia and systemic symptoms;Myalgia;Pruritus,124247101,OT,,,124247101,1,20160504,20160523,,,124247101,1,Product used for unknown indication
12425160,124251601,1,I,,20160525,20160601,20160601,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-041462,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20160601,,PH,GB,GB,SUSTIVA,Metabolic surgery,124251601,OT,,,,,,,,,124251601,1,Product used for unknown indication
12427266,124272661,1,I,,20160526,20160602,20160602,PER,,US-GILEAD-2016-0216105,GILEAD,,,,,F,Y,,,20160601,,OT,US,US,EFAVIRENZ,Skin ulcer,,,,,,,,,,,124272661,1,Hepatitis C
12428752,124287521,1,I,,20160526,20160602,20160602,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-042132,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20160602,,MD,US,US,EFAVIRENZ,Skin ulcer,124287521,OT,,,,,,,,,124287521,1,Hepatitis C
12436882,124368822,2,F,,20160523,20160606,20160606,EXP,,ES-CIPLA LTD.-2016ES06033,CIPLA,"NEUKAM K, ESPINOSA N, COLLADO A, DELGADO-FERNANDEZ M, JIMENEZ-AGUILAR P, RIVERO-JUAREZ A ET AL. HEPATIC SAFETY OF RILPIVIRINE/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE FIXED-DOSE SINGLE-TABLET REGIMEN IN HIV-INFECTED PATIENTS WITH ACTIVE HEPATITIS C VIRUS INFECTION: THE HEPATIC STUDY. PLOS ONE. 2016;11 (5):1 TO 13",,,,,Y,,,20160606,,OT,ES,ES,Efavirenz,Gastrointestinal haemorrhage;Portal hypertension,124368822,OT,,,,,,,,,124368822,1,Antiretroviral therapy
12438204,124382041,1,I,,20160526,20160606,20160606,EXP,,GB-MYLANLABS-2016M1023075,MYLAN,,,,,,Y,,,20160606,,CN,GB,GB,SUSTIVA,Death,124382041,OT,,,,,,,,,124382041,1,Product used for unknown indication
12438406,124384061,1,I,2011,20150917,20160606,20160606,EXP,,US-DSJP-DSU-2015-129563,DAIICHI,,,,,F,Y,58.5,KG,20160606,,CN,US,US,SUSTIVA,Malabsorption,124384061,HO,,,124384061,1,2009,2012,,,124384061,1,Hypertension
12439298,124392983,3,F,20160115,20160614,20160606,20160622,EXP,,IT-GILEAD-2016-0216502,GILEAD,,67,YR,E,M,Y,65,KG,20160622,,OT,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Lumbar vertebral fracture;Osteoporosis,124392983,HO,,,124392983,1,20050620,20160609,,,124392983,1,HIV infection
12439378,124393781,1,I,20150414,20150512,20160606,20160606,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2015GSK065465,VIIV,,36,YR,,M,Y,,,20160606,,MD,UG,UG,EFAVIRENZ,Anaemia,124393781,HO,,,124393781,1,20141205,20150421,,,124393781,1,HIV infection
12443612,124436121,1,I,,20160523,20160607,20160607,EXP,,"ES-ROXANE LABORATORIES, INC.-2016-RO-01016RO",ROXANE,"FERNANEDEZ-ALVAREZ R,GONZALEZ-RODRIGUEZ A,RUBIO-CASTRO A,ESTHER GONZALEZ M,ET AL. BORTEZOMIB PLUS CHOP FOR THE TREATMENT OF HIV ASSOCIATED PLASMABLASTIC LYMPHOMA: CLINICAL EXPERIENCE IN THREE PATIENTS. LEUKEMIA AND LYMPHOMA 2016 FEB;57:2:463-466.",39,YR,,M,Y,,,20160607,,OT,COUNTRY NOT SPECIFIED,ES,EFAVIRENZ,Anaemia;Neutropenia;Peripheral sensorimotor neuropathy;Sepsis;Thrombocytopenia,124436121,OT,,,,,,,,,124436121,1,Plasmablastic lymphoma
12445087,124450871,1,I,20130801,20131114,20160607,20160607,EXP,,DE-BMSGILMSD-2013-0088290,GILEAD,,,,A,F,Y,73,KG,20160607,,MD,DE,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion induced;Pregnancy,,,,,,,,,,,124450871,1,HIV infection
12446686,124466861,1,I,,20160525,20160608,20160608,EXP,,US-CIPLA LTD.-2016US06201,CIPLA,"WARRICK BJ, TATARU AP, SMOLINSKE S. A SYSTEMATIC ANALYSIS OF METHYLENE BLUE FOR DRUG-INDUCED SHOCK. CLINICAL TOXICOLOGY. 2016;1 TO 9",,,,,Y,,,20160608,,OT,US,US,Efavirenz,Cardiogenic shock;Coma;Lactic acidosis;Overdose;Polyuria;Renal failure,124466861,HO,,,,,,,,,124466861,1,HIV infection
12448035,124480351,1,I,,20160601,20160608,20160608,EXP,,FR-GILEAD-2016-0216869,GILEAD,"DE CASTRO N, GAUBE G, GUEGEN A, LASCOUX C, ZAGDANSKI A, ALANIO A, MOLINA J. TREATMENT WITH ADALIMUMAB FOR SEVERE IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN AN HIV-INFECTED PATIENT PRESENTING WITH CRYPTOCOCCAL MENINGITIS. MEDECINE ET MALADIES INFECTIEUSES. 2016;46(3):154-156",33,YR,A,F,Y,,,20160608,,OT,FR,FR,EFAVIRENZ,Bipolar disorder,124480351,OT,,,124480351,1,201106,201106,,,124480351,1,HIV infection
12449585,124495851,1,I,,20160413,20160609,20160609,PER,,KE-LUPIN PHARMACEUTICALS INC.-2016-01618,LUPIN,"TARUS N, PAU A, SERETI I, KIRUI F, SAWE F, AGAN B, MOMANYI L, NGENO H, KOSKEI G, SHAFFER D. CHALLENGES IN MANAGEMENT OF WARFARIN ANTI-COAGULATION IN ADVANCED HIV/AIDS PATIENTS WITH VENOUS THROMBOTIC EVENTS- A CASE SERIES FROM A RESEARCH CLINIC IN RURAL KERICHO, KENYA.. EAST AFRICAN MEDICAL JOURNAL. 2013;90(7):207-213.",30,YR,,M,Y,,,20160608,,PH,KE,KE,Efavirenz,Drug interaction;International normalised ratio abnormal,,,,,,,,,,,124495851,1,Deep vein thrombosis
12449588,124495881,1,I,,20160413,20160609,20160609,PER,,KE-LUPIN PHARMACEUTICALS INC.-2016-01640,LUPIN,"TARUS N, PAU A, SERETI I, KIRUI F, SAWE F, AGAN B, MOMANYI L, NGENO H, KOSKEI G, SHAFFER D. CHALLENGES IN MANAGEMENT OF WARFARIN ANTI-COAGULATION IN ADVANCED HIV/AIDS PATIENTS WITH VENOUS THROMBOTIC EVENTS- A CASE SERIES FROM A RESEARCH CLINIC IN RURAL KERICHO, KENYA.. EAST AFRICAN MEDICAL JOURNAL. 2013;90(7):207-213.",47,YR,,F,Y,,,20160608,,PH,KE,KE,Efavirenz,Drug interaction;International normalised ratio abnormal,,,,,,,,,,,124495881,1,Deep vein thrombosis
12449603,124496031,1,I,,20160413,20160609,20160609,PER,,KE-LUPIN PHARMACEUTICALS INC.-2016-01641,LUPIN,"TARUS N, PAU A, SERETI I, KIRUI F, SAWE F, AGAN B, MOMANYI L, NGENO H, KOSKEI G, SHAFFER D. CHALLENGES IN MANAGEMENT OF WARFARIN ANTI-COAGULATION IN ADVANCED HIV/AIDS PATIENTS WITH VENOUS THROMBOTIC EVENTS- A CASE SERIES FROM A RESEARCH CLINIC IN RURAL KERICHO, KENYA.. EAST AFRICAN MEDICAL JOURNAL. 2013;90(7):207-213.",39,YR,,F,Y,,,20160608,,PH,KE,KE,Efavirenz,Drug interaction;International normalised ratio abnormal,,,,,,,,,,,124496031,1,Deep vein thrombosis
12449604,124496041,1,I,,20160413,20160609,20160609,PER,,KE-LUPIN PHARMACEUTICALS INC.-2016-01642,LUPIN,"TARUS N, PAU A, SERETI I, KIRUI F, SAWE F, AGAN B, MOMANYI L, NGENO H, KOSKEI G, SHAFFER D. CHALLENGES IN MANAGEMENT OF WARFARIN ANTI-COAGULATION IN ADVANCED HIV/AIDS PATIENTS WITH VENOUS THROMBOTIC EVENTS- A CASE SERIES FROM A RESEARCH CLINIC IN RURAL KERICHO, KENYA.. EAST AFRICAN MEDICAL JOURNAL. 2013;90(7):207-213.",31,YR,,M,Y,,,20160608,,PH,KE,KE,Efavirenz,Drug interaction;International normalised ratio abnormal,,,,,,,,,,,124496041,1,Deep vein thrombosis
12449605,124496051,1,I,,20160413,20160609,20160609,PER,,KE-LUPIN PHARMACEUTICALS INC.-2016-01644,LUPIN,"TARUS N, PAU A, SERETI I, KIRUI F, SAWE F, AGAN B, MOMANYI L, NGENO H, KOSKEI G, SHAFFER D. CHALLENGES IN MANAGEMENT OF WARFARIN ANTI-COAGULATION IN ADVANCED HIV/AIDS PATIENTS WITH VENOUS THROMBOTIC EVENTS- A CASE SERIES FROM A RESEARCH CLINIC IN RURAL KERICHO, KENYA.. EAST AFRICAN MEDICAL JOURNAL. 2013;90(7):207-213.",38,YR,,F,Y,,,20160608,,PH,KE,KE,Efavirenz,Drug interaction;International normalised ratio abnormal,,,,,,,,,,,124496051,1,Deep vein thrombosis
12450753,124507531,1,I,20160607,,20160608,20160608,DIR,,,,,51,YR,,M,N,,,20160607,N,PH,US,,SUSTIVA,Suicidal ideation,,,124507531,HP,,,,,,,,,
12451404,124514041,1,I,20160417,20160602,20160609,20160609,EXP,,FR-PFIZER INC-2016286912,PFIZER,,45,YR,,M,Y,,,20160609,,OT,FR,FR,EFAVIRENZ,Acute kidney injury;Encephalopathy;Epilepsy;Hyperkalaemia;Hyponatraemia,124514041,HO,,,124514041,7,2016,,,,124514041,1,Oral fungal infection
12455700,124557001,1,I,,20160527,20160610,20160610,EXP,,US-CIPLA LTD.-2016US06391,CIPLA,,,,,,Y,,,20160610,,OT,US,US,Efavirenz,Adverse event;Drug interaction,124557001,OT,,,,,,,,,124557001,1,HIV infection
12456925,124569251,1,I,,20160603,20160610,20160610,EXP,,ZW-GILEAD-2016-0217550,GILEAD,,33,YR,A,F,Y,47,KG,20160610,,MD,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Kaposi's sarcoma,124569251,DE,,,124569251,1,20160120,20160516,,,124569251,1,Kaposi's sarcoma AIDS related
12458098,124580981,1,I,,20160530,20160613,20160613,EXP,,GB-HETERO LABS LTD-1053713,HETERO,,43,YR,,F,Y,,,20160613,,CN,US,GB,SUSTIVA,Death,124580981,DE,,,,,,,,,124580981,1,Product used for unknown indication
12459270,124592702,2,F,,20160616,20160613,20160622,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2016GSK083624,VIIV,,,,,M,Y,,,20160622,,CN,GB,GB,Efavirenz,Cerebral haemorrhage;Rib fracture,124592702,OT,,,,,,,,,124592702,1,Product used for unknown indication
12462340,124623402,2,F,,20160606,20160613,20160629,EXP,,RU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-045024,BRISTOL MYERS SQUIBB,,30,YR,,F,Y,,,20160629,,CN,RU,RU,EFAVIRENZ,Dizziness;Nausea;Nightmare,124623402,OT,,,124623402,1,20160110,20160124,,,124623402,1,HIV infection
12463934,124639341,1,I,,20160606,20160614,20160614,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2016GSK080757,VIIV,,62,YR,,,Y,,,20160614,,CN,GB,GB,Efavirenz,Arthralgia;Chronic obstructive pulmonary disease;Fatigue;Pancreatic injury;Type 2 diabetes mellitus;Weight decreased,124639341,OT,,,,,,,,,124639341,1,HIV infection
12464219,124642191,1,I,,20160607,20160614,20160614,EXP,,CZ-GLAXOSMITHKLINE-CZ2016GSK084203,GLAXOSMITHKLINE,"ROMERO CF, SOTO-HERNANDEZ JL, BONNET C, AND CARDENAS G. MENINGIOMATOSIS IN AN AIDS PATIENT RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART). THE NEUROLOGIST. 2016;21(3):44-46",27,YR,,M,Y,,,20160614,,MD,MX,CZ,Efavirenz,Hoffmann's sign;Hyperreflexia;Insomnia;Meningioma;Papilloedema;Weight decreased,124642191,OT,,,,,,,,,124642191,1,Acquired immunodeficiency syndrome
12467582,124675821,1,I,,20160607,20160615,20160615,EXP,,CZ-VIIV HEALTHCARE LIMITED-CZ2016GSK084203,VIIV,"ROMERO CF, SOTO-HERNANDEZ JL, BONNET C, AND CARDENAS G. MENINGIOMATOSIS IN AN AIDS PATIENT RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART). THE NEUROLOGIST. 2016;21(3):44-46",27,YR,,M,Y,,,20160615,,MD,MX,CZ,Efavirenz,Hoffmann's sign;Hyperreflexia;Insomnia;Meningioma;Papilloedema;Weight decreased,124675821,OT,,,,,,,,,124675821,1,Acquired immunodeficiency syndrome
12474411,124744111,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06876,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Pyrexia;Virologic failure,124744111,OT,,,,,,,,,124744111,1,HIV infection
12474441,124744411,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06880,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Blood alkaline phosphatase increased;Virologic failure,124744411,OT,,,,,,,,,124744411,1,HIV infection
12474456,124744561,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06879,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Hypoalbuminaemia;Virologic failure,124744561,OT,,,,,,,,,124744561,1,HIV infection
12474528,124745281,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06883,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Herpes simplex;Virologic failure,124745281,OT,,,,,,,,,124745281,1,HIV infection
12474536,124745361,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06877,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Cardiac disorder;Virologic failure,124745361,OT,,,,,,,,,124745361,1,HIV infection
12474544,124745441,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06878,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Nervous system disorder;Virologic failure,124745441,OT,,,,,,,,,124745441,1,HIV infection
12474970,124749701,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06888,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Tuberculosis;Virologic failure,124749701,DE,,,,,,,,,124749701,1,HIV infection
12474974,124749741,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06887,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Genitourinary symptom;Renal disorder;Virologic failure,124749741,OT,,,,,,,,,124749741,1,HIV infection
12474979,124749791,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07169,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Gastroenteritis;Virologic failure,124749791,OT,,,,,,,,,124749791,1,HIV infection
12474983,124749831,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07170,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Cerebrovascular accident;Virologic failure,124749831,DE,,,,,,,,,124749831,1,HIV infection
12475358,124753581,1,I,,20160604,20160617,20160617,EXP,,UG-AUROBINDO-AUR-APL-2016-07882,AUROBINDO,,64,YR,,M,Y,,,20160616,,OT,BE,UG,Efavirenz,Blood creatinine increased;Nephropathy toxic;Proteinuria,124753581,OT,,,,,,,,,124753581,1,Antiretroviral therapy
12475439,124754391,1,I,,20160604,20160617,20160617,EXP,,UG-AUROBINDO-AUR-APL-2016-07894,AUROBINDO,,52,YR,,M,Y,,,20160616,,OT,BE,UG,Efavirenz,Blood creatinine increased;Nephropathy toxic,124754391,LT,,,,,,,,,124754391,1,Antiretroviral therapy
12475442,124754421,1,I,,20160604,20160617,20160617,EXP,,UG-AUROBINDO-AUR-APL-2016-07907,AUROBINDO,,38,YR,,F,Y,,,20160616,,OT,BE,UG,Efavirenz,Blood creatinine increased;Nephropathy toxic;Proteinuria,124754421,OT,,,,,,,,,124754421,1,Antiretroviral therapy
12475443,124754431,1,I,,20160604,20160617,20160617,EXP,,UG-AUROBINDO-AUR-APL-2016-07900,AUROBINDO,,28,YR,,M,Y,,,20160616,,OT,BE,UG,Efavirenz,Blood creatinine increased;Nephropathy toxic;Proteinuria;Renal tubular necrosis,124754431,OT,,,,,,,,,124754431,1,Antiretroviral therapy
12475478,124754781,1,I,,20160604,20160617,20160617,EXP,,UG-AUROBINDO-AUR-APL-2016-07960,AUROBINDO,,22,YR,,F,Y,,,20160617,,OT,BE,UG,Efavirenz,Blood creatinine increased;Nephropathy toxic,124754781,OT,,,,,,,,,124754781,1,Antiretroviral therapy
12475486,124754861,1,I,,20160604,20160617,20160617,EXP,,UG-AUROBINDO-AUR-APL-2016-08026,AUROBINDO,,39,YR,,F,Y,,,20160617,,OT,BE,UG,Efavirenz,Bone density decreased;Nephropathy toxic,124754861,OT,,,,,,,,,124754861,1,Antiretroviral therapy
12475487,124754871,1,I,,20160604,20160617,20160617,EXP,,UG-AUROBINDO-AUR-APL-2016-08004,AUROBINDO,,38,YR,,M,Y,,,20160617,,OT,BE,UG,Efavirenz,Anaemia;Death;Hydronephrosis;Nephropathy toxic;Proteinuria,124754871,DE,,,,,,,,,124754871,1,Antiretroviral therapy
12475492,124754921,1,I,,20160604,20160617,20160617,EXP,,UG-AUROBINDO-AUR-APL-2016-07952,AUROBINDO,,48,YR,,F,Y,,,20160617,,OT,BE,UG,EFAVIRENZ,Blood creatinine increased;Nephropathy toxic,124754921,OT,,,,,,,,,124754921,1,Antiretroviral therapy
12475493,124754931,1,I,,20160604,20160617,20160617,EXP,,UG-AUROBINDO-AUR-APL-2016-07967,AUROBINDO,,38,YR,,F,Y,,,20160617,,OT,BE,UG,Efavirenz,Blood creatinine increased;Nephropathy toxic,124754931,OT,,,124754931,1,2006,,,,124754931,1,Antiretroviral therapy
12475494,124754941,1,I,,20160604,20160617,20160617,EXP,,UG-AUROBINDO-AUR-APL-2016-07961,AUROBINDO,,52,YR,,M,Y,,,20160617,,OT,BE,UG,Efavirenz,Blood creatinine increased;Nephropathy toxic,124754941,OT,,,,,,,,,124754941,1,Antiretroviral therapy
12475499,124754991,1,I,,20160604,20160617,20160617,EXP,,UG-AUROBINDO-AUR-APL-2016-07991,AUROBINDO,,30,YR,,F,Y,,,20160617,,OT,BE,UG,Efavirenz,Blood urine present;Nephropathy toxic,124754991,OT,,,,,,,,,124754991,1,Antiretroviral therapy
12476247,124762471,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07183,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Treatment noncompliance;Virologic failure,124762471,OT,,,,,,,,,124762471,1,HIV infection
12476249,124762491,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07185,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Virologic failure,124762491,OT,,,,,,,,,124762491,1,HIV infection
12476250,124762501,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06884,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,AIDS dementia complex;Virologic failure,124762501,OT,,,,,,,,,124762501,1,HIV infection
12476252,124762521,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07179,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Herpes simplex;Virologic failure,124762521,OT,,,,,,,,,124762521,1,HIV infection
12476253,124762531,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07296,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Skin reaction;Virologic failure,124762531,OT,,,,,,,,,124762531,1,HIV infection
12476254,124762541,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07297,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Adverse event;Virologic failure,124762541,OT,,,,,,,,,124762541,1,HIV infection
12476255,124762551,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07182,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Depression;Virologic failure,124762551,OT,,,,,,,,,124762551,1,HIV infection
12476256,124762561,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07177,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Cervix carcinoma;Virologic failure,124762561,OT,,,,,,,,,124762561,1,HIV infection
12476257,124762571,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07263,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Drug resistance;Virologic failure,124762571,OT,,,,,,,,,124762571,1,HIV infection
12476258,124762581,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07173,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Carbon dioxide increased;Virologic failure,124762581,OT,,,,,,,,,124762581,1,HIV infection
12476259,124762591,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07178,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Meningitis cryptococcal;Virologic failure,124762591,OT,,,,,,,,,124762591,1,HIV infection
12476261,124762611,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07172,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Blood alkaline phosphatase increased;Virologic failure,124762611,OT,,,,,,,,,124762611,1,HIV infection
12476262,124762621,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06881,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Anaemia;Virologic failure,124762621,OT,,,,,,,,,124762621,1,HIV infection
12476264,124762641,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07171,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Adverse event;Virologic failure,124762641,OT,,,,,,,,,124762641,1,HIV infection
12476266,124762661,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07262,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Drug resistance;Virologic failure,124762661,OT,,,,,,,,,124762661,1,HIV infection
12476269,124762691,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06890,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Kaposi's sarcoma AIDS related;Virologic failure,124762691,DE,,,,,,,,,124762691,1,HIV infection
12476270,124762701,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07175,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Pancreatic disorder;Virologic failure,124762701,OT,,,,,,,,,124762701,1,HIV infection
12476272,124762721,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06886,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Deep vein thrombosis;Virologic failure,124762721,OT,,,,,,,,,124762721,1,HIV infection
12476273,124762731,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06885,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Acute myocardial infarction;Virologic failure,124762731,OT,,,,,,,,,124762731,1,HIV infection
12476274,124762741,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06891,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Acute respiratory failure;Virologic failure,124762741,OT,,,,,,,,,124762741,1,HIV infection
12476275,124762751,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07181,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Cerebrovascular accident;Virologic failure,124762751,OT,,,,,,,,,124762751,1,HIV infection
12476280,124762801,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07184,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Virologic failure,124762801,OT,,,,,,,,,124762801,1,HIV infection
12476281,124762811,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07295,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Drug resistance;Virologic failure,124762811,OT,,,,,,,,,124762811,1,HIV infection
12476282,124762821,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06889,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Sepsis;Virologic failure,124762821,DE,,,,,,,,,124762821,1,HIV infection
12476283,124762831,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07261,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Drug resistance;Virologic failure,124762831,OT,,,,,,,,,124762831,1,HIV infection
12476284,124762841,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07176,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Pneumonia bacterial;Virologic failure,124762841,OT,,,,,,,,,124762841,1,HIV infection
12476285,124762851,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07174,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Hyperglycaemia;Virologic failure,124762851,OT,,,,,,,,,124762851,1,HIV infection
12476286,124762861,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US07180,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Gastroenteritis;Virologic failure,124762861,OT,,,,,,,,,124762861,1,HIV infection
12476345,124763451,1,I,,20160603,20160617,20160617,EXP,,US-CIPLA LTD.-2016US06882,CIPLA,,,,,,Y,,,20160617,,OT,PE,US,Efavirenz,Pneumonia bacterial;Virologic failure,124763451,OT,,,,,,,,,124763451,1,HIV infection
12481920,124819201,1,I,20160405,20160610,20160620,20160620,EXP,,US-GILEAD-2016-0218879,GILEAD,,,,,F,Y,,,20160620,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Parathyroid disorder;Viral infection,124819201,HO,,,,,,,,,124819201,1,HIV infection
12483822,124838221,1,I,,20160614,20160621,20160621,EXP,,US-STRIDES ARCOLAB LIMITED-2016SP007727,STRIDES,,,,,,Y,,,20160621,,OT,US,BR,EFAVIRENZ,Congenital skin dimples;Foetal exposure during pregnancy;Peyronie's disease,124838221,CA,,,,,,,,,124838221,1,Product used for unknown indication
12485003,124850031,1,I,,20160610,20160621,20160621,EXP,,GB-GLAXOSMITHKLINE-GB2016GSK083624,GLAXOSMITHKLINE,,,,,M,Y,,,20160621,,CN,GB,GB,Efavirenz,Cerebral haemorrhage;Rib fracture,124850031,HO,,,,,,,,,124850031,1,Product used for unknown indication
12486495,124864951,1,I,,20160613,20160621,20160621,EXP,,US-BMSGILMSD-2016-0219037,GILEAD,,47,YR,A,M,Y,,,20160621,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Multiple fractures;Road traffic accident;Swelling,124864951,HO,,,,,,,,,124864951,1,HIV infection
12487051,124870512,2,F,,20160610,20160622,20160622,EXP,,UG-CIPLA LTD.-2016UG07220,CIPLA,"SEKAGGYA C, NALWANGA D, BRAUN AV, NAKIJOBA R, KAMBUGU A, FEHR J ET.AL.,. CHALLENGES IN ACHIEVING A TARGET INTERNATIONAL NORMALIZED RATIO FOR DEEP VEIN THROMBOSIS AMONG HIV-INFECTED PATIENTS WITH TUBERCULOSIS: A CASE SERIES. BMC HEMATOLOGY. 2016;16(16):1 TO 5",,,,,Y,,,20160622,,OT,UG,UG,Efavirenz,Anticoagulation drug level below therapeutic;Cryptococcal fungaemia;Drug interaction;International normalised ratio increased,124870512,OT,,,,,,,,,124870512,1,HIV infection
12487210,124872101,1,I,20151201,20160614,20160622,20160622,EXP,,IT-GILEAD-2016-0219320,GILEAD,,54,YR,A,F,Y,,,20160621,,PH,IT,IT,SUSTIVA,Blood cholesterol increased;Fatigue;Headache,124872101,OT,,,124872101,1,20151201,20160515,,,124872101,1,Chronic hepatitis C
12487439,124874392,2,F,,20160610,20160622,20160622,EXP,,UG-CIPLA LTD.-2016UG07222,CIPLA,"SEKAGGYA C, NALWANGA D, VON BRAUN A, NAKIJOBA R, KAMBUGU A, FEHR J ET.AL,. CHALLENGES IN ACHIEVING A TARGET INTERNATIONAL NORMALIZED RATIO FOR DEEP VEIN THROMBOSIS AMONG HIV-INFECTED PATIENTS WITH TUBERCULOSIS: A CASE SERIES. BMC HEMATOLOGY. 2016;16 (16):1 TO 5",,,,,Y,,,20160622,,OT,UG,UG,Efavirenz,Deep vein thrombosis;Drug interaction;Epistaxis;International normalised ratio increased,124874392,OT,,,,,,,,,124874392,1,HIV infection
12487535,124875352,2,F,,20160610,20160622,20160622,EXP,,UG-CIPLA LTD.-2016UG07313,CIPLA,"SEKAGGYA C, NALWANGA D, VON BRAUN A, NAKIJOBA R, KAMBUGU A, FEHR J ET.AL. CHALLENGES IN ACHIEVING A TARGET INTERNATIONAL NORMALIZED RATIO FOR DEEP VEIN THROMBOSIS AMONG HIV-INFECTED PATIENTS WITH TUBERCULOSIS: A CASE SERIES. BMC HEMATOLOGY. 2016;16:16:1 TO 5",,,,,Y,,,20160622,,OT,UG,UG,Efavirenz,Cryptococcal fungaemia;Deep vein thrombosis;Drug interaction;Epistaxis;International normalised ratio increased,124875352,OT,,,,,,,,,124875352,1,HIV infection
12487536,124875362,2,F,,20160610,20160622,20160622,EXP,,UG-CIPLA LTD.-2016UG07310,CIPLA,"SEKAGGYA C, NALWANGA D, BRAUN AV, NAKIJOBA R, KAMBUGU A, FEHR J ET AL.,. CHALLENGES IN ACHIEVING A TARGET INTERNATIONAL NORMALIZED RATIO FOR DEEP VEIN THROMBOSIS AMONG HIV-INFECTED PATIENTS WITH TUBERCULOSIS: A CASE SERIES. BMC HEMATOLOGY. 2016;16 (16):1 TO 5",,,,,Y,,,20160622,,OT,UG,UG,Efavirenz,Deep vein thrombosis;Treatment noncompliance,124875362,OT,,,,,,,,,124875362,1,HIV infection
12487546,124875462,2,F,,20160610,20160622,20160622,EXP,,UG-CIPLA LTD.-2016UG07221,CIPLA,"SEKAGGYA C, NALWANGA D, VON BRAUN A, NAKIJOBA R, KAMBUGU A, FEHR J ET.AL.,. CHALLENGES IN ACHIEVING A TARGET INTERNATIONAL NORMALIZED RATIO FOR DEEP VEIN THROMBOSIS AMONG HIV-INFECTED PATIENTS WITH TUBERCULOSIS: A CASE SERIES. BMC HEMATOLOGY. 2016;16(16):1 TO 5",,,,,Y,,,20160622,,OT,UG,UG,Efavirenz,Deep vein thrombosis;Drug interaction;International normalised ratio increased,124875462,OT,,,,,,,,,124875462,1,HIV infection
12487549,124875492,2,F,,20160610,20160622,20160622,EXP,,UG-CIPLA LTD.-2016UG07314,CIPLA,"SEKAGGYA C, NALWANGA D, VON BRAUN A, NAKIJOBA R, KAMBUGU A, FEHR J, ET.AL,. CHALLENGES IN ACHIEVING A TARGET INTERNATIONAL NORMALIZED RATIO FOR DEEP VEIN THROMBOSIS AMONG HIV-INFECTED PATIENTS WITH TUBERCULOSIS: A CASE SERIES. BMC HEMATOLOGY. 2016;16 (16):1 TO 5",,,,,Y,,,20160622,,OT,UG,UG,Efavirenz,Deep vein thrombosis;Drug interaction;International normalised ratio increased,124875492,OT,,,,,,,,,124875492,1,HIV infection
12487554,124875542,2,F,,20160610,20160622,20160622,EXP,,UG-CIPLA LTD.-2016UG07315,CIPLA,"SEKAGGYA C, NALWANGA D, BRAUN AV, NAKIJOBA R, KAMBUGU A, FEHR J ET.AL. CHALLENGES IN ACHIEVING A TARGET INTERNATIONAL NORMALIZED RATIO FOR DEEP VEIN THROMBOSIS AMONG HIV-INFECTED PATIENTS WITH TUBERCULOSIS: A CASE SERIES. BMC HEMATOLOGY. 2016;16 (16):1 TO 5",,,,,Y,,,20160622,,OT,UG,UG,Efavirenz,Cryptococcal fungaemia;Deep vein thrombosis;Treatment noncompliance,124875542,OT,,,,,,,,,124875542,1,HIV infection
12493624,124936241,1,I,,20160614,20160623,20160623,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2016GSK087530,VIIV,"JOSE. SK, MARFATIA. YS. ERYTHEMA ELEVATUM DIUTINUM IN ACQUIRED IMMUNE DEFICIENCY SYNDROME: CAN IT BE AN IMMUNE. INDIAN JOURNAL OF SEXUALLY TRANSMITTED DISEASES. 2016;37:81-84",47,YR,,M,Y,,,20160623,,MD,IN,IN,Efavirenz,CD4 lymphocytes decreased;Cough;Cutaneous tuberculosis;Dyspnoea;Erythema elevatum diutinum;Fatigue;Fibrosis;Immune reconstitution inflammatory syndrome;Kaposi's sarcoma;Nodule;Pain;Pruritus;Rash papular;Skin lesion;Weight decreased,124936241,OT,,,124936241,1,2009,,,,124936241,1,HIV infection
12493672,124936721,1,I,,20160614,20160623,20160623,EXP,,IN-GLAXOSMITHKLINE-IN2016GSK087530,GLAXOSMITHKLINE,"JOSE. SK, MARFATIA. YS. ERYTHEMA ELEVATUM DIUTINUM IN ACQUIRED IMMUNE DEFICIENCY SYNDROME: CAN IT BE AN IMMUNE. INDIAN JOURNAL OF SEXUALLY TRANSMITTED DISEASES. 2016;37:81-84",47,YR,,M,Y,,,20160623,,MD,IN,IN,Efavirenz,CD4 lymphocytes decreased;Cough;Cutaneous tuberculosis;Dyspnoea;Erythema elevatum diutinum;Fatigue;Fibrosis;Immune reconstitution inflammatory syndrome;Kaposi's sarcoma;Nodule;Pain;Pruritus;Rash papular;Skin lesion;Weight decreased,124936721,OT,,,124936721,1,2009,,,,124936721,1,HIV infection
12496510,124965102,2,F,20160618,20160623,20160624,20160630,EXP,,MX-GLAXOSMITHKLINE-MX2016GSK089328,GLAXOSMITHKLINE,,37,YR,,M,Y,79.5,KG,20160630,,CN,MX,MX,Efavirenz,Eosinophilia;Face oedema;Ill-defined disorder;Insomnia;Laryngeal oedema;Nausea;Pyrexia;Rash generalised;Skin lesion;Tachycardia;Urticaria,124965102,OT,,,124965102,1,20160610,20160618,,,124965102,1,Product used for unknown indication
12498402,124984022,2,F,20160618,20160623,20160627,20160630,EXP,,MX-VIIV HEALTHCARE LIMITED-MX2016GSK089328,VIIV,,37,YR,,M,Y,79.5,KG,20160630,,CN,MX,MX,Efavirenz,Eosinophilia;Face oedema;Ill-defined disorder;Insomnia;Laryngeal oedema;Nausea;Pyrexia;Rash generalised;Skin lesion;Tachycardia;Urticaria,124984022,OT,,,124984022,1,20160610,20160618,,,124984022,1,Product used for unknown indication
12502978,125029781,1,I,20040806,20060718,20160628,20160628,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-13454525,BRISTOL MYERS SQUIBB,,46,YR,,M,Y,,,20160628,,CN,JP,JP,EFAVIRENZ,Diabetes mellitus;Hepatic function abnormal;Hypercholesterolaemia;Hypertriglyceridaemia;Lipoatrophy,125029781,OT,,,125029781,1,20030304,20050304,,,125029781,1,HIV infection
12506038,125060381,1,I,,20160620,20160628,20160628,EXP,,GB-MYLANLABS-2016M1025869,MYLAN,,,,,,Y,,,20160628,,CN,GB,GB,EFAVIRENZ,Cerebral haemorrhage;Rib fracture,125060381,HO,,,,,,,,,125060381,1,Product used for unknown indication
12506557,125065571,1,I,,20160621,20160628,20160628,EXP,,US-BMSGILMSD-2016-0220325,GILEAD,,,,,M,Y,,,20160628,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Arthralgia;Ascites;Hepatic cirrhosis;Liver disorder;Neuropathy peripheral;Splenomegaly;T-lymphocyte count decreased,125065571,OT,,,125065571,1,19950106,,,,125065571,1,HIV infection
12507979,125079791,1,I,,20160623,20160629,20160629,EXP,,DE-VIIV HEALTHCARE LIMITED-DE2016GSK089842,VIIV,,40,YR,,M,Y,,,20160629,,CN,DE,DE,SUSTIVA,Delirium;Drug therapeutic incompatibility;Dysstasia;Malaise;Nightmare,125079791,OT,,,,,,,,,125079791,1,HIV infection
6902323,69023235,5,F,20070614,20160620,20090205,20160629,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-14445084,BRISTOL MYERS SQUIBB,,58,YR,,M,Y,,,20160629,,CN,JP,JP,EFAVIRENZ,Diabetes mellitus;Myasthenia gravis,69023235,OT,,,69023235,1,20030124,20100119,,,69023235,1,HIV infection
8691284,86912848,8,F,20090824,20160412,20120730,20160420,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-16789448,BRISTOL MYERS SQUIBB,,41,YR,,M,Y,,,20160420,,CN,JP,JP,EFAVIRENZ,Diabetes mellitus;Full blood count decreased;Hepatitis C,86912848,OT,,,86912848,1,20000901,20100711,,,86912848,1,HIV infection
8696154,86961547,7,F,20090824,20160412,20120801,20160415,EXP,,JP-009507513-1207JPN000172,MERCK,,41,YR,,M,Y,,,20160415,,CN,JP,JP,EFAVIRENZ,Diabetes mellitus;Full blood count decreased;Hepatitis C,86961547,OT,,,86961547,1,20000901,20100711,,,86961547,1,HIV infection
9899895,98998953,3,F,20131121,20160428,20140214,20160502,EXP,,TH-BRISTOL-MYERS SQUIBB COMPANY-19888817,BRISTOL MYERS SQUIBB,,34,YR,,F,Y,38.25,KG,20160502,,CN,US,TH,EFAVIRENZ,Disease progression;Systemic lupus erythematosus,98998953,HO,,,98998953,1,20120111,20140115,,,98998953,1,HIV infection
